Journal Article
. 2018 Apr; 378(22):2093-2104.
doi: 10.1056/NEJMoa1801946.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D Hellmann 1 Tudor-Eliade Ciuleanu 1 Adam Pluzanski 1 Jong Seok Lee 1 Gregory A Otterson 1 Clarisse Audigier-Valette 1 Elisa Minenza 1 Helena Linardou 1 Sjaak Burgers 1 Pamela Salman 1 Hossein Borghaei 1 Suresh S Ramalingam 1 Julie Brahmer 1 Martin Reck 1 Kenneth J O'Byrne 1 William J Geese 1 George Green 1 Han Chang 1 Joseph Szustakowski 1 Prabhu Bhagavatheeswaran 1 Diane Healey 1 Yali Fu 1 Faith Nathan 1 Luis Paz-Ares 1 
  • PMID: 29658845
  •     19 References
  •     1085 citations


Background: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase).

Methods: We enrolled patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy. Those with a level of tumor programmed death ligand 1 (PD-L1) expression of at least 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy; those with a tumor PD-L1 expression level of less than 1% were randomly assigned, in a 1:1:1 ratio, to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy. Tumor mutational burden was determined by the FoundationOne CDx assay.

Results: Progression-free survival among patients with a high tumor mutational burden was significantly longer with nivolumab plus ipilimumab than with chemotherapy. The 1-year progression-free survival rate was 42.6% with nivolumab plus ipilimumab versus 13.2% with chemotherapy, and the median progression-free survival was 7.2 months (95% confidence interval [CI], 5.5 to 13.2) versus 5.5 months (95% CI, 4.4 to 5.8) (hazard ratio for disease progression or death, 0.58; 97.5% CI, 0.41 to 0.81; P<0.001). The objective response rate was 45.3% with nivolumab plus ipilimumab and 26.9% with chemotherapy. The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD-L1 expression level of at least 1% and those with a level of less than 1%. The rate of grade 3 or 4 treatment-related adverse events was 31.2% with nivolumab plus ipilimumab and 36.1% with chemotherapy. ical; CheckMate 227 number, NCT02477826 .).

Conclusions: Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, +21 authors, Garrett M Frampton.
Genome Med, 2017 Apr 20; 9(1). PMID: 28420421    Free PMC article.
Highly Cited.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
James X Sun, Yuting He, +9 authors, Roman Yelensky.
PLoS Comput Biol, 2018 Feb 08; 14(2). PMID: 29415044    Free PMC article.
Highly Cited.
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Nasser Hanna, David Johnson, Sarah Temin, Gregory Masters.
J Oncol Pract, 2017 Aug 30; 13(12). PMID: 28850309
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, +29 authors, Matthew D Hellmann.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29337640    Free PMC article.
Highly Cited.
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, +32 authors, Miranda Hughes.
J Natl Compr Canc Netw, 2017 Apr 14; 15(4). PMID: 28404761
Highly Cited.
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
Pedro Nazareth Aguiar, Ramon Andrade De Mello, +4 authors, Gilberto de Lima Lopes.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209522    Free PMC article.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, +43 authors, Luis A Diaz.
Science, 2017 Jun 10; 357(6349). PMID: 28596308    Free PMC article.
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
M M Oken, R H Creech, +4 authors, P P Carbone.
Am J Clin Oncol, 1982 Dec 01; 5(6). PMID: 7165009
Highly Cited.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D Hellmann, Naiyer A Rizvi, +14 authors, Scott J Antonia.
Lancet Oncol, 2016 Dec 10; 18(1). PMID: 27932067    Free PMC article.
Highly Cited.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee.
N Engl J Med, 2017 Dec 21; 377(25). PMID: 29262275    Free PMC article.
Highly Cited.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Tavi Nathanson, +29 authors, Jedd D Wolchok.
Cancer Cell, 2018 Apr 17; 33(5). PMID: 29657128    Free PMC article.
Highly Cited.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Matthew D Hellmann, Margaret K Callahan, +13 authors, Scott J Antonia.
Cancer Cell, 2018 May 08; 33(5). PMID: 29731394    Free PMC article.
Highly Cited.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, +27 authors, CheckMate 026 Investigators.
N Engl J Med, 2017 Jun 22; 376(25). PMID: 28636851    Free PMC article.
Highly Cited.
Rethinking medulloblastoma from a targeted therapeutics perspective.
Yuuri Hashimoto, Marta Penas-Prado, +11 authors, Amy Heimberger.
J Neurooncol, 2018 Jun 06; 139(3). PMID: 29869738    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.
Megan B Barnet, Wendy A Cooper, Michael J Boyer, Steven Kao.
J Clin Med, 2018 Jun 16; 7(6). PMID: 29904031    Free PMC article.
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.
Tamkin Ahmadzada, Steven Kao, +3 authors, Wendy A Cooper.
J Clin Med, 2018 Jun 20; 7(6). PMID: 29914100    Free PMC article.
Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
Andrew C Tiu, Rashmika Potdar, +2 authors, Claudia Dourado.
Med Oncol, 2018 Jun 20; 35(7). PMID: 29915891
The role of radiology in the evaluation of the immunotherapy efficacy.
Marco Calandri, Federica Solitro, +2 authors, Andrea Veltri.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951295    Free PMC article.
Toxicities and outcomes: Do steroids matter?
Douglas B Johnson.
Cancer, 2018 Jul 06; 124(18). PMID: 29975416    Free PMC article.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Julie R Brahmer, Ramaswamy Govindan, +18 authors, Roy S Herbst.
J Immunother Cancer, 2018 Jul 18; 6(1). PMID: 30012210    Free PMC article.
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC.
Juliet A Carmichael, Daisy Wing-San Mak, Mary O'Brien.
Cancers (Basel), 2018 Jul 20; 10(7). PMID: 30021993    Free PMC article.
Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math.
Frank A Giordano, Marlon R Veldwijk, Carsten Herskind, Frederik Wenz.
Strahlenther Onkol, 2018 Jul 22; 194(10). PMID: 30030581
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Michael Flynn, Kate Young, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034550    Free PMC article.
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Olivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, Christos Chouaïd.
Onco Targets Ther, 2018 Jul 25; 11. PMID: 30038505    Free PMC article.
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060457    Free PMC article.
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060526    Free PMC article.
Highly Cited. Review.
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Andrea Botticelli, Bruna Cerbelli, +7 authors, Paolo Marchetti.
J Transl Med, 2018 Aug 08; 16(1). PMID: 30081936    Free PMC article.
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Jingjing Duan, Yu Wang, Shunchang Jiao.
Cancer Med, 2018 Aug 09; 7(9). PMID: 30088347    Free PMC article.
Personalized therapy for lung cancer: striking a moving target.
Suchita Pakkala, Suresh S Ramalingam.
JCI Insight, 2018 Aug 10; 3(15). PMID: 30089719    Free PMC article.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Beatriz Wills, Julie R Brahmer, Jarushka Naidoo.
Curr Treat Options Oncol, 2018 Aug 14; 19(9). PMID: 30101402    Free PMC article.
New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.
Jiajia Zhang, Shafat Quadri, Christopher L Wolfgang, Lei Zheng.
Biomedicines, 2018 Aug 15; 6(3). PMID: 30104497    Free PMC article.
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
Robert Pirker.
ESMO Open, 2018 Aug 18; 3(5). PMID: 30116594    Free PMC article.
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.
Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122997    Free PMC article.
Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?
Jumpei Kashima, Yusuke Okuma.
J Thorac Dis, 2018 Aug 21; 10(Suppl 18). PMID: 30123539    Free PMC article.
Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching.
Mary M Huerter, Apar Kishor Ganti.
J Thorac Dis, 2018 Aug 21; 10(Suppl 18). PMID: 30123559    Free PMC article.
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
David A Fabrizio, Thomas J George, +13 authors, Samuel J Klempner.
J Gastrointest Oncol, 2018 Aug 29; 9(4). PMID: 30151257    Free PMC article.
Highly Cited.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, +23 authors, A Drilon.
Ann Oncol, 2018 Aug 31; 29(10). PMID: 30165371    Free PMC article.
Highly Cited.
Roche splashes $2.4 billion on Foundation Medicine's cancer platform.
Cormac Sheridan.
Nat Biotechnol, 2018 Sep 07; 36(9). PMID: 30188548
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer.
Steven Lehrer, Peter H Rheinstein.
Cancer Genomics Proteomics, 2018 Sep 09; 15(5). PMID: 30194079    Free PMC article.
POLE gene hotspot mutations in advanced pancreatic cancer.
Michael Guenther, Vivien Veninga, +8 authors, Steffen Ormanns.
J Cancer Res Clin Oncol, 2018 Sep 09; 144(11). PMID: 30194485
Combining immunotherapy with radiation therapy in thoracic oncology.
Shahed N Badiyan, Michael C Roach, +7 authors, Charles B Simone.
J Thorac Dis, 2018 Sep 13; 10(Suppl 21). PMID: 30206494    Free PMC article.
[Molecular predictors in immune oncology].
W Weichert.
Pathologe, 2018 Sep 15; 39(6). PMID: 30215118
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer.
Yanis Boumber.
J Thorac Dis, 2018 Sep 21; 10(8). PMID: 30233840    Free PMC article.
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Francesco Facchinetti, Paola Bordi, +2 authors, Marcello Tiseo.
Drug Des Devel Ther, 2018 Sep 22; 12. PMID: 30237696    Free PMC article.
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).
Ori Wald.
J Clin Med, 2018 Sep 28; 7(10). PMID: 30257500    Free PMC article.
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Maria I Toki, Nikita Mani, +7 authors, David L Rimm.
J Thorac Oncol, 2018 Sep 30; 13(12). PMID: 30267840    Free PMC article.
DNA repair defects and implications for immunotherapy.
Katherine M Bever, Dung T Le.
J Clin Invest, 2018 Oct 03; 128(10). PMID: 30272580    Free PMC article.
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Akio Osa, Takeshi Uenami, +30 authors, Atsushi Kumanogoh.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282824    Free PMC article.
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
Jingjing Duan, Yongwei Xie, +6 authors, Shunchang Jiao.
J Immunother Cancer, 2018 Oct 05; 6(1). PMID: 30285868    Free PMC article.
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences.
Xinyu Yan, Shouyue Zhang, +3 authors, Heng Xu.
Front Pharmacol, 2018 Oct 09; 9. PMID: 30294272    Free PMC article.
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.
Daniel H Johnson, Chrystia M Zobniw, +21 authors, Adi Diab.
J Immunother Cancer, 2018 Oct 12; 6(1). PMID: 30305177    Free PMC article.
Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota.
Mengxue Dong, Zhefeng Meng, +7 authors, Li Ye.
Cell Death Dis, 2018 Oct 12; 9(10). PMID: 30305604    Free PMC article.
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Masaki Kanazu, Ryuya Edahiro, +7 authors, Masahide Mori.
Thorac Cancer, 2018 Oct 18; 9(12). PMID: 30328672    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Predictive biomarkers for tumor immune checkpoint blockade.
Mengting Tong, Jing Wang, +4 authors, Hongliang Zhang.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349382    Free PMC article.
Exploring optimal sequencing of radiation and immunotherapy combinations.
Andrew J Gunderson, Kristina H Young.
Adv Radiat Oncol, 2018 Oct 30; 3(4). PMID: 30370348    Free PMC article.
A new era of treating advanced lung cancer is upon us.
Glen J Weiss.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393601    Free PMC article.
Identification of a novel therapeutic target in driver-negative non-small cell lung cancer.
Motonobu Saito, Koji Kono, Takashi Kohno.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393606    Free PMC article.
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393608    Free PMC article.
LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.
Rachael Chang Lee, Bibhusal Thapa, Thomas John.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393612    Free PMC article.
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Wolfram C M Dempke, Klaus Fenchel, Stephen P Dale.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393621    Free PMC article.
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Alfredo Addeo, Giuseppe Luigi Banna.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393623    Free PMC article.
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Giulio Metro, Massimo Di Maio.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393625    Free PMC article.
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Silvia C Formenti, Nils-Petter Rudqvist, +15 authors, Sandra Demaria.
Nat Med, 2018 Nov 07; 24(12). PMID: 30397353    Free PMC article.
Highly Cited.
30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Jacobus Adrianus Burgers, Ronald Alphons Damhuis.
ERJ Open Res, 2018 Nov 09; 4(4). PMID: 30406123    Free PMC article.
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
Xingxiang Pu, Lin Wu, +2 authors, Bingliang Fang.
BMC Cancer, 2018 Nov 10; 18(1). PMID: 30409126    Free PMC article.
Non-small cell lung cancer: land of conquest for immunotherapy.
Enrico Munari, Giuseppe Bogina.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416763    Free PMC article.
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Ying L Liu, Dmitriy Zamarin.
Curr Oncol Rep, 2018 Nov 14; 20(12). PMID: 30421009    Free PMC article.
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy.
Arutha Kulasinghe, Hanjie Wu, Chamindie Punyadeera, Majid Ebrahimi Warkiani.
Micromachines (Basel), 2018 Nov 15; 9(8). PMID: 30424330    Free PMC article.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
Precision oncology: separating the wheat from the chaff.
Jordi Remon, Rodrigo Dienstmann.
ESMO Open, 2018 Nov 15; 3(6). PMID: 30425845    Free PMC article.
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.
Federica Papaccio, Carminia Maria Della Corte, +5 authors, Floriana Morgillo.
Int J Mol Sci, 2018 Nov 18; 19(11). PMID: 30441809    Free PMC article.
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Francesco Sabbatino, Antonio Marra, +5 authors, Stefano Pepe.
J Immunother Cancer, 2018 Nov 22; 6(1). PMID: 30458852    Free PMC article.
Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC.
Hangjun Wang, Alan Spatz.
Oncotarget, 2018 Nov 23; 9(84). PMID: 30464800    Free PMC article.
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
Jake R Conway, Eric Kofman, +2 authors, Eliezer Van Allen.
Genome Med, 2018 Dec 01; 10(1). PMID: 30497521    Free PMC article.
A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Ruchi Chaudhary, Luca Quagliata, +7 authors, Fiona Hyland.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505706    Free PMC article.
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke, Paul Hofman.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505707    Free PMC article.
The clinical utility of tumor mutational burden in non-small cell lung cancer.
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505708    Free PMC article.
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Lizza E Hendriks, Etienne Rouleau, Benjamin Besse.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505709    Free PMC article.
Methods of measurement for tumor mutational burden in tumor tissue.
Bárbara Meléndez, Claude Van Campenhout, +3 authors, Nicky D'Haene.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505710    Free PMC article.
Highly Cited. Review.
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.
Francesca Fenizia, Raffaella Pasquale, +3 authors, Nicola Normanno.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505711    Free PMC article.
Approach to evaluating tumor mutational burden in routine clinical practice.
John Truesdell, Vincent A Miller, David Fabrizio.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505712    Free PMC article.
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?
Matthew Evans, Brendan O'Sullivan, Matthew Smith, Philippe Taniere.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505713    Free PMC article.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.
Frédérique Penault-Llorca, Nina Radosevic-Robin.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505716    Free PMC article.
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Michael Allgäuer, Jan Budczies, +13 authors, Albrecht Stenzinger.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505715    Free PMC article.
Highly Cited. Review.
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.
Lisa H Butterfield, Mary L Disis, +4 authors, Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers.
J Immunother Cancer, 2018 Dec 06; 6(1). PMID: 30514399    Free PMC article.
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.
Stefan Diem, Mirjam Fässler, +9 authors, Lukas Flatz.
Cancer Manag Res, 2018 Dec 07; 10. PMID: 30519101    Free PMC article.
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.
Jan Budczies, Anja Seidel, +7 authors, Carsten Denkert.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524909    Free PMC article.
Determination of human γδ T cell-mediated cytotoxicity using a non-radioactive assay system.
Mohammed S O Tagod, Satoshi Mizuta, +6 authors, Yoshimasa Tanaka.
J Immunol Methods, 2019 Jan 18; 466. PMID: 30654042    Free PMC article.
Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics.
Santiago Ramón Y Cajal, Stefan Hümmer, +5 authors, Javier Hernandez-Losa.
Histopathology, 2019 Jan 23; 75(1). PMID: 30667539    Free PMC article.
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Padmanee Sharma, Arlene Siefker-Radtke, +14 authors, Jonathan Rosenberg.
J Clin Oncol, 2019 May 18; 37(19). PMID: 31100038    Free PMC article.
The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
Liang Peng, Jin-Qi Liu, Yu-Pei Chen, Jun Ma.
Br J Radiol, 2019 May 22; 92(1102). PMID: 31112398    Free PMC article.
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, +7 authors, Ying Cheng.
J Clin Lab Anal, 2019 Jul 10; 33(8). PMID: 31282096    Free PMC article.
Highly Cited.
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
Mingjia Li, Daniel Spakowicz, +11 authors, Dwight H Owen.
J Cancer Res Clin Oncol, 2019 Aug 02; 145(10). PMID: 31367835    Free PMC article.
Novel Delivery Systems for Checkpoint Inhibitors.
Purushottam Lamichhane, Rahul Deshmukh, +8 authors, Narottam Lamichhane.
Medicines (Basel), 2019 Aug 03; 6(3). PMID: 31373327    Free PMC article.
Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade.
Netonia Marshall, Keino Hutchinson, +7 authors, Joshua D Brody.
Cancer Discov, 2019 Aug 04; 9(11). PMID: 31375522    Free PMC article.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park, Lynette M Sholl, +2 authors, Mizuki Nishino.
Radiology, 2019 Aug 07; 293(1). PMID: 31385753    Free PMC article.
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P Bonaca, Benjamin A Olenchock, +17 authors, Javid Moslehi.
Circulation, 2019 Aug 08; 140(2). PMID: 31390169    Free PMC article.
Highly Cited. Review.
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Todd C Knepper, Meagan Montesion, +13 authors, Andrew S Brohl.
Clin Cancer Res, 2019 Aug 11; 25(19). PMID: 31399473    Free PMC article.
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
Sandra D Griffith, Rebecca A Miksad, +10 authors, Amy P Abernethy.
JCO Clin Cancer Inform, 2019 Aug 14; 3. PMID: 31403818    Free PMC article.
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Aaron M Goodman, Ethan S Sokol, +2 authors, Razelle Kurzrock.
Cancer Immunol Res, 2019 Aug 14; 7(10). PMID: 31405947    Free PMC article.
Panel-based estimates of tumor mutational burden: characterizing unknown unknowns.
W Yang, L G T Morris, T A Chan.
Ann Oncol, 2019 Aug 15; 30(9). PMID: 31410441    Free PMC article.
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.
Sanjeevani Arora, Rodion Velichinskii, +6 authors, Yanis Boumber.
Adv Ther, 2019 Aug 15; 36(10). PMID: 31410780    Free PMC article.
Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma.
Gwendolen Lorch, Karthigayini Sivaprakasam, +16 authors, William P D Hendricks.
Clin Cancer Res, 2019 Aug 23; 25(19). PMID: 31431454    Free PMC article.
Novel Biomarkers for Personalized Cancer Immunotherapy.
Yoshitaro Shindo, Shoichi Hazama, +2 authors, Hiroaki Nagano.
Cancers (Basel), 2019 Aug 25; 11(9). PMID: 31443339    Free PMC article.
Circulating biomarkers predictive of tumor response to cancer immunotherapy.
Ernest Y Lee, Rajan P Kulkarni.
Expert Rev Mol Diagn, 2019 Aug 31; 19(10). PMID: 31469965    Free PMC article.
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Adrien Costantini, Paul Takam Kamga, +3 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470546    Free PMC article.
In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.
Simon Heeke, Jonathan Benzaquen, +17 authors, Paul Hofman.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470674    Free PMC article.
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ja Yoon Heo, Changhee Park, +8 authors, Dae Seog Heo.
Thorac Cancer, 2019 Sep 12; 10(11). PMID: 31509890    Free PMC article.
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
Catherine R Sears, Tobias Peikert, +11 authors, M Patricia Rivera.
Am J Respir Crit Care Med, 2019 Sep 14; 200(6). PMID: 31518182    Free PMC article.
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer].
Xia Liu, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Sep 19; 22(9). PMID: 31526463    Free PMC article.
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.
Petros Grivas, Bradley J Monk, +6 authors, Markus Moehler.
Target Oncol, 2019 Sep 20; 14(5). PMID: 31535338
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Yu Chen, Gang Chen, +14 authors, Jian-Ji Pan.
JAMA Netw Open, 2019 Sep 21; 2(9). PMID: 31539077    Free PMC article.
Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.
Malgorzata Bobrowicz, Radoslaw Zagozdzon, +3 authors, Magdalena Winiarska.
Cancers (Basel), 2019 Sep 27; 11(10). PMID: 31554169    Free PMC article.
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors.
Misako Nagasaka, Nadine Abdallah, +6 authors, Ammar Sukari.
Lung Cancer (Auckl), 2019 Oct 02; 10. PMID: 31572037    Free PMC article.
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
Andrea Bianco, Fabio Perrotta, +3 authors, Raffaele De Palma.
Int J Mol Sci, 2019 Oct 09; 20(19). PMID: 31590386    Free PMC article.
Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Chen Yang, Frances Austin, +5 authors, Scott A Turner.
Cold Spring Harb Mol Case Stud, 2019 Oct 13; 5(5). PMID: 31604779    Free PMC article.
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
Ibrahim Halil Sahin, Mehmet Akce, +4 authors, Christina Wu.
Br J Cancer, 2019 Oct 15; 121(10). PMID: 31607751    Free PMC article.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
Mike Nguyen, Md Rafiqul Islam, +2 authors, Babak Tamjid.
Front Oncol, 2019 Oct 15; 9. PMID: 31608234    Free PMC article.
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness.
Haitang Yang, Shun-Qing Liang, Ralph A Schmid, Ren-Wang Peng.
Front Oncol, 2019 Oct 16; 9. PMID: 31612108    Free PMC article.
NK Cell-Fc Receptors Advance Tumor Immunotherapy.
Emilio Sanseviero.
J Clin Med, 2019 Oct 17; 8(10). PMID: 31614774    Free PMC article.
Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.
Hiroki Izumi, Masahiro Kodani, +13 authors, Akira Yamasaki.
Mol Clin Oncol, 2019 Oct 17; 11(5). PMID: 31616560    Free PMC article.
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Cheng Fang, Chu Zhang, +3 authors, Mei Ji.
BMC Med Genomics, 2019 Oct 18; 12(1). PMID: 31619231    Free PMC article.
Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor.
B Martín-Antonio, G Suñe, +12 authors, A Urbano-Ispizua.
J Immunother Cancer, 2019 Oct 18; 7(1). PMID: 31619273    Free PMC article.
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Hao-Xiang Wu, Yan-Xing Chen, +5 authors, Rui-Hua Xu.
J Immunother Cancer, 2019 Oct 19; 7(1). PMID: 31623662    Free PMC article.
Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.
Wenya Su, Wenlu Xiao, +5 authors, Zhigang Wang.
Onco Targets Ther, 2019 Oct 22; 12. PMID: 31632065    Free PMC article.
Blood tumor mutational burden: are we ready for clinical implementation?
Claude Van Campenhout, Bárbara Meléndez, +2 authors, Nicky D'Haene.
J Thorac Dis, 2019 Oct 22; 11(Suppl 15). PMID: 31632782    Free PMC article.
Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
Ya-Fang Huang, Wen-Jie Xie, Hai-Yu Fan, Juan Du.
Front Oncol, 2019 Oct 22; 9. PMID: 31632907    Free PMC article.
Systematic Review.
Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Amanda Frydendahl Boll Johansen, Christine Gaasdal Kassentoft, +6 authors, Claus Lindbjerg Andersen.
BMC Cancer, 2019 Oct 23; 19(1). PMID: 31638937    Free PMC article.
Pan-cancer whole-genome analyses of metastatic solid tumours.
Peter Priestley, Jonathan Baber, +18 authors, Edwin Cuppen.
Nature, 2019 Oct 28; 575(7781). PMID: 31645765    Free PMC article.
Highly Cited.
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center.
Noura J Choudhury, Mansooreh Eghtesad, +5 authors, Jyoti D Patel.
Oncotarget, 2019 Oct 28; 10(56). PMID: 31645901    Free PMC article.
MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.
Yufeng Lv, Zhong Huang, +5 authors, Zihai Xu.
Oncoimmunology, 2019 Oct 28; 8(10). PMID: 31646073    Free PMC article.
A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.
Sarah Lévesque, Julie Le Naour, +12 authors, Jonathan G Pol.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646107    Free PMC article.
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
David Lang, Florian Huemer, +9 authors, Bernd Lamprecht.
Target Oncol, 2019 Oct 28; 14(6). PMID: 31654203    Free PMC article.
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
Guanghui Gao, Meng Qiao, +8 authors, Caicun Zhou.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656652    Free PMC article.
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.
Thiago Pimentel Muniz, Victor Hugo Fonseca de Jesus, +2 authors, Vladmir Cláudio Cordeiro de Lima.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656665    Free PMC article.
Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration.
Boyang Zhao, Justin R Pritchard.
PLoS Comput Biol, 2019 Oct 29; 15(10). PMID: 31658270    Free PMC article.
Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Jianfei Yao, Yuan Gong, +12 authors, Lele Song.
Sci Rep, 2019 Nov 02; 9(1). PMID: 31673068    Free PMC article.
Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG).
George Zarkavelis, Vassiliki Kotoula, +17 authors, George Pentheroudakis.
ESMO Open, 2019 Nov 02; 4(5). PMID: 31673425    Free PMC article.
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.
Kongju Wu, Ming Yi, +3 authors, Kongming Wu.
Exp Hematol Oncol, 2019 Nov 02; 8. PMID: 31673481    Free PMC article.
PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.
Andrew Bang, Jonathan D Schoenfeld, Alexander Y Sun.
Transl Lung Cancer Res, 2019 Nov 02; 8(Suppl 2). PMID: 31673518    Free PMC article.
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Diane Damotte, Sarah Warren, +21 authors, Karen Leroy.
J Transl Med, 2019 Nov 07; 17(1). PMID: 31684954    Free PMC article.
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Farastuk Bozorgmehr, Adriane Hommertgen, +9 authors, Stefan Rieken.
BMC Cancer, 2019 Nov 11; 19(1). PMID: 31703637    Free PMC article.
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Qing-Qing Chai, Jiang-Yang Du, Jun Zhu, Bin Wu.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708783    Free PMC article.
Systematic Review.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Hannah L Buckley, Fiona J Collinson, +15 authors, Naveen S Vasudev.
BMC Cancer, 2019 Nov 16; 19(1). PMID: 31727024    Free PMC article.
KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.
Amy Lauren Cummings, Kate M Santoso, Jonathan W Goldman.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737507    Free PMC article.
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno, Afshin Dowlati.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737508    Free PMC article.
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J Walsh, Ross A Soo.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737512    Free PMC article.
Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis.
Hang Xu, Ping Tan, +5 authors, Qiang Wei.
Front Pharmacol, 2019 Nov 22; 10. PMID: 31749704    Free PMC article.
Systematic Review.
The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Yongfeng Wu, Jinming Xu, +4 authors, Jian Hu.
Front Oncol, 2019 Nov 22; 9. PMID: 31750249    Free PMC article.
Systematic Review.
Tumor mutational burden in lung cancer: a systematic literature review.
Connor Willis, Michelle Fiander, +6 authors, David D Stenehjem.
Oncotarget, 2019 Nov 26; 10(61). PMID: 31762941    Free PMC article.
Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Yuqiao Chen, Yuan Zhou, +4 authors, Wei Zhuang.
J Cancer, 2019 Nov 28; 10(25). PMID: 31772659    Free PMC article.
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Megan Greally, Joanne F Chou, +16 authors, Geoffrey Y Ku.
Clin Cancer Res, 2019 Jul 25; 25(20). PMID: 31337644    Free PMC article.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Maria V Bermudez, Sophie Papa.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816083    Free PMC article.
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Matthew B Schabath, Tapashi B Dalvi, +13 authors, Jhanelle E Gray.
Cancer Manag Res, 2019 Dec 11; 11. PMID: 31819612    Free PMC article.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carmine Carbone, Geny Piro, +9 authors, Emilio Bria.
Mediators Inflamm, 2019 Dec 13; 2019. PMID: 31827379    Free PMC article.
[Importance of tumour mutation burden testing].
Peter J Wild.
Pathologe, 2019 Dec 07; 40(Suppl 3). PMID: 31807843
Biomarker for personalized immunotherapy.
Si-Yang Liu, Yi-Long Wu.
Transl Lung Cancer Res, 2019 Dec 21; 8(Suppl 3). PMID: 31857954    Free PMC article.
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Keum Hwa Lee, +12 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 07; 11(11). PMID: 31683809    Free PMC article.
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Andreas Kronbichler, +5 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 17; 11(11). PMID: 31731749    Free PMC article.
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
Natalie I Vokes, David Liu, +19 authors, Mark M Awad.
JCO Precis Oncol, 2019 Dec 14; 3. PMID: 31832578    Free PMC article.
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.
Hannah Petrek, Ai-Ming Yu.
Pharmacol Res Perspect, 2019 Dec 21; 7(6). PMID: 31859460    Free PMC article.
Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens.
Lei Zhao, Jing Yu, +3 authors, Bangwei Cao.
J Cancer, 2020 Jan 02; 11(1). PMID: 31892971    Free PMC article.
Significant function and research progress of biomarkers in gastric cancer.
Dong Mei Ye, Gaosheng Xu, +5 authors, Zhiwei Zhang.
Oncol Lett, 2020 Jan 04; 19(1). PMID: 31897111    Free PMC article.
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Yan Zhang, Xuexiang Du, +9 authors, Yang Liu.
Cell Res, 2019 Jul 04; 29(8). PMID: 31267017    Free PMC article.
The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.
Shuang Li, Shuang Zhang, +3 authors, Ying Cheng.
J Thorac Dis, 2020 Jan 07; 11(11). PMID: 31903233    Free PMC article.
PD-1 Inhibitors in the Advanced Esophageal Cancer.
Ye Hong, Zhen-Yu Ding.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920637    Free PMC article.
Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Malte Roerden, Annika Nelde, Juliane S Walz.
Front Immunol, 2020 Jan 11; 10. PMID: 31921218    Free PMC article.
Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study.
Valentina Masciale, Giulia Grisendi, +7 authors, Beatrice Aramini.
Front Oncol, 2020 Jan 11; 9. PMID: 31921651    Free PMC article.
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Yu-Tong Chen, Sharvesh Raj Seeruttun, Xiang-Yuan Wu, Zi-Xian Wang.
Front Oncol, 2020 Jan 11; 9. PMID: 31921683    Free PMC article.
Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
Xiuju Liang, Yaping Guan, +4 authors, Jun Wang.
Front Oncol, 2020 Jan 11; 9. PMID: 31921686    Free PMC article.
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Emilio Sanseviero, Erin M O'Brien, +16 authors, Erica L Stone.
Cancer Immunol Res, 2019 Jun 27; 7(8). PMID: 31239316    Free PMC article.
Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers.
Hao-Xiang Wu, Zi-Xian Wang, +9 authors, Feng Wang.
Ann Transl Med, 2020 Jan 14; 7(22). PMID: 31930041    Free PMC article.
Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Ying Li, Wenbin Jiang, +10 authors, Zheng Guo.
J Transl Med, 2020 Jan 16; 18(1). PMID: 31937321    Free PMC article.
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.
Fan Zhang, Di Huang, +13 authors, Yi Hu.
J Cancer, 2020 Jan 17; 11(3). PMID: 31942197    Free PMC article.
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Kabir Mody, Jason Starr, +5 authors, Anthony F Shields.
J Gastrointest Oncol, 2020 Jan 18; 10(6). PMID: 31949927    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Samuel J Klempner, David Fabrizio, +8 authors, Prasanth Reddy.
Oncologist, 2019 Oct 04; 25(1). PMID: 31578273    Free PMC article.
Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Pham Nguyen Quy, Masashi Kanai, +16 authors, Manabu Muto.
Oncologist, 2019 Jun 13; 24(12). PMID: 31186376    Free PMC article.
Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Jian Xie, Zewen Zhang, +4 authors, Yuan Tian.
Medicine (Baltimore), 2019 Dec 20; 98(50). PMID: 31852114    Free PMC article.
Systematic Review.
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Ilaria Alborelli, Katharina Leonards, +12 authors, Philip Jermann.
J Pathol, 2019 Sep 01; 250(1). PMID: 31471895    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers.
David Tai, Su Pin Choo, Valerie Chew.
Cancers (Basel), 2019 Dec 11; 11(12). PMID: 31816940    Free PMC article.
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Sohyun Hwang, Ah-Young Kwon, +7 authors, Hee Jung An.
Sci Rep, 2020 Jan 22; 10(1). PMID: 31959763    Free PMC article.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Thierry Landre, Gaetan Des Guetz, +3 authors, Christos Chouaïd.
J Cancer Res Clin Oncol, 2019 Nov 07; 146(2). PMID: 31686247
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Hisao Imai, Satoshi Wasamoto, +15 authors, Kyoichi Kaira.
J Cancer Res Clin Oncol, 2019 Dec 20; 146(2). PMID: 31853661
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.
Emanuelle M Rizk, Angelina M Seffens, +5 authors, Yvonne M Saenger.
Am J Clin Dermatol, 2019 Oct 12; 21(1). PMID: 31602560    Free PMC article.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Alessio Cortellini, Sebastiano Buti, +46 authors, Corrado Ficorella.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002308    Free PMC article.
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Tina Krieger, Isobel Pearson, +2 authors, Paul Robbins.
Diagn Pathol, 2020 Feb 01; 15(1). PMID: 32000815    Free PMC article.
Comprehensive T cell repertoire characterization of non-small cell lung cancer.
Alexandre Reuben, Jiexin Zhang, +55 authors, Jianjun Zhang.
Nat Commun, 2020 Feb 01; 11(1). PMID: 32001676    Free PMC article.
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Arsela Prelaj, Roberto Ferrara, +19 authors, Giuseppe Lo Russo.
Cancers (Basel), 2019 Dec 11; 11(12). PMID: 31817541    Free PMC article.
Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Steven D Criss, Lauren Palazzo, +4 authors, Chung Yin Kong.
PLoS One, 2020 Jan 30; 15(1). PMID: 31995619    Free PMC article.
Phagocytosis checkpoints as new targets for cancer immunotherapy.
Mingye Feng, Wen Jiang, +3 authors, Irving L Weissman.
Nat Rev Cancer, 2019 Aug 30; 19(10). PMID: 31462760    Free PMC article.
Highly Cited. Review.
Tumor immune response and immunotherapy in gastric cancer.
Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee.
J Pathol Transl Med, 2019 Nov 02; 54(1). PMID: 31674166    Free PMC article.
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Wungki Park, Laura Mezquita, +14 authors, Gilberto Lopes.
Br J Cancer, 2019 Nov 26; 122(3). PMID: 31761899    Free PMC article.
Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Elisabeth Smolle, Katharina Leithner, Horst Olschewski.
Thorac Cancer, 2019 Dec 05; 11(2). PMID: 31799812    Free PMC article.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Alejandro Ruiz-Patiño, Oscar Arrieta, +28 authors, CLICaP.
Thorac Cancer, 2019 Dec 13; 11(2). PMID: 31828967    Free PMC article.
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Zhengyang Hu, Ming Li, +3 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010587    Free PMC article.
EGFR mutations in lung cancer: not all equal in the eyes of the immune system?
Kwun M Fong, Brett G M Hughes, Zarnie Lwin, Ian A Yang.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016044    Free PMC article.
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Kamila Wojas-Krawczyk, Ewa Kalinka, +2 authors, Janusz Milanowski.
Int J Mol Sci, 2019 Apr 21; 20(8). PMID: 31003463    Free PMC article.
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
Andrea Botticelli, Pamela Vernocchi, +13 authors, Paolo Marchetti.
J Transl Med, 2020 Feb 06; 18(1). PMID: 32014010    Free PMC article.
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Pascale Tomasini, Laurent Greillier.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038906    Free PMC article.
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock.
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038915    Free PMC article.
Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
Ninadh M D'Costa, Matthew R Lowerison, +9 authors, Alan I So.
J Exp Clin Cancer Res, 2020 Feb 12; 39(1). PMID: 32041631    Free PMC article.
[Immunohistochemical and molecular pathological diagnosis of lung carcinoma].
Britta Janina Wagner, Reinhard Buettner.
Pathologe, 2020 Jan 15; 41(1). PMID: 31932944
The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer.
Isabel Alvarado-Cruz, Rithy Meas, +3 authors, Joann Balazs Sweasy.
Mutagenesis, 2019 Dec 28; 35(1). PMID: 31880305    Free PMC article.
Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.
Ninadh M D'Costa, Davide Cina, +8 authors, Alan I So.
Sci Rep, 2020 Feb 08; 10(1). PMID: 32029828    Free PMC article.
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.
Ashley E Ross, Paula J Hurley, +9 authors, Emmanuel S Antonarakis.
Prostate Cancer Prostatic Dis, 2019 Oct 16; 23(1). PMID: 31611635    Free PMC article.
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
Di Huang, Fan Zhang, +10 authors, Yi Hu.
Target Oncol, 2020 Feb 14; 15(1). PMID: 32052340
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lijun Da, Yuanjun Teng, +4 authors, Feixue Song.
Front Pharmacol, 2020 Feb 23; 10. PMID: 32082164    Free PMC article.
Systematic Review.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
J Cell Physiol, 2019 Nov 07; 235(5). PMID: 31693178    Free PMC article.
Systematic Review.
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
Caroline A Nebhan, Douglas B Johnson.
Expert Rev Anticancer Ther, 2020 Jan 31; 20(2). PMID: 31997676    Free PMC article.
A Rare Case of Advanced Urethral Diverticular Adenocarcinoma and a Review of Treatment Modalities.
Fatai Oluyadi, Preethi Ramachandran, Vladmir Gotlieb.
J Investig Med High Impact Case Rep, 2019 Feb 12; 7. PMID: 30739492    Free PMC article.
Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.
Ravi A Madan, James L Gulley.
J Natl Cancer Inst, 2018 Oct 16; 111(3). PMID: 30321404    Free PMC article.
Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
Kenneth L Kehl, Christopher S Lathan, Bruce E Johnson, Deborah Schrag.
J Natl Cancer Inst, 2018 Dec 24; 111(4). PMID: 30576459    Free PMC article.
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
Cansu Cimen Bozkus, Vladimir Roudko, +4 authors, Nina Bhardwaj.
Cancer Discov, 2019 Jul 04; 9(9). PMID: 31266769    Free PMC article.
Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer.
Benedikt Martin, Bruno Märkl.
Visc Med, 2019 Jul 18; 35(1). PMID: 31312644    Free PMC article.
Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
Hana Noskova, Michal Kyr, +10 authors, Ondrej Slaby.
Cancers (Basel), 2020 Jan 23; 12(1). PMID: 31963488    Free PMC article.
Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
Richard K Yang, Yun Qing, +9 authors, Russell R Broaddus.
Oncotarget, 2020 Feb 29; 11(6). PMID: 32110280    Free PMC article.
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
Yi Yang, Gang Jin, +7 authors, Zijiang Zhu.
Front Pharmacol, 2020 Mar 03; 11. PMID: 32116716    Free PMC article.
Systematic Review.
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
Alex Friedlaender, Thierry Nouspikel, +3 authors, Alfredo Addeo.
Front Oncol, 2020 Mar 03; 10. PMID: 32117779    Free PMC article.
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Katsuyuki Hotta, Nobukazu Fujimoto.
J Immunother Cancer, 2020 Feb 27; 8(1). PMID: 32098830    Free PMC article.
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
Michael Offin, Hira Rizvi, +12 authors, Matthew D Hellmann.
Clin Cancer Res, 2018 Jul 27; 25(3). PMID: 30045933    Free PMC article.
Highly Cited.
Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?
Michael L Cheng, Geoffrey R Oxnard.
Clin Cancer Res, 2018 Sep 08; 25(3). PMID: 30190372    Free PMC article.
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, +18 authors, Erica L Carpenter.
JAMA Oncol, 2018 Oct 17; 5(2). PMID: 30325992    Free PMC article.
Highly Cited.
The intimate relationship between gut microbiota and cancer immunotherapy.
Arielle Elkrief, Lisa Derosa, +2 authors, Bertrand Routy.
Gut Microbes, 2018 Oct 20; 10(3). PMID: 30339501    Free PMC article.
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, +4 authors, S Peters.
Ann Oncol, 2018 Nov 06; 30(1). PMID: 30395155    Free PMC article.
Highly Cited. Review.
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.
Jarushka Naidoo, Arbor Dykema, Franco D'Alessio.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530990    Free PMC article.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Steven D Criss, Meghan J Mooradian, +5 authors, Chung Yin Kong.
JAMA Oncol, 2018 Dec 14; 5(3). PMID: 30543349    Free PMC article.
The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Arutha Kulasinghe, Joanna Kapeleris, +6 authors, Chamindie Punyadeera.
Cancer Med, 2018 Dec 20; 7(12). PMID: 30565869    Free PMC article.
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Juan Ruiz-Bañobre, Ajay Goel.
Gastroenterology, 2018 Dec 24; 156(4). PMID: 30578781    Free PMC article.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Roman M Chabanon, Gareth Muirhead, +20 authors, Sophie Postel-Vinay.
J Clin Invest, 2018 Dec 28; 129(3). PMID: 30589644    Free PMC article.
Highly Cited.
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Mattia Boeri, Massimo Milione, +11 authors, Gabriella Sozzi.
Clin Cancer Res, 2019 Jan 09; 25(7). PMID: 30617131    Free PMC article.
Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence.
Katey S S Enfield, Spencer D Martin, +10 authors, Martial Guillaud.
J Immunother Cancer, 2019 Jan 18; 7(1). PMID: 30651131    Free PMC article.
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Albrecht Stenzinger, Jeffrey D Allen, +4 authors, Manfred Dietel.
Genes Chromosomes Cancer, 2019 Jan 22; 58(8). PMID: 30664300    Free PMC article.
Highly Cited. Review.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Ana C Garrido-Castro, Nancy U Lin, Kornelia Polyak.
Cancer Discov, 2019 Jan 27; 9(2). PMID: 30679171    Free PMC article.
Highly Cited. Review.
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Matthew J Bott, Stephen C Yang, +11 authors, Stephen R Broderick.
J Thorac Cardiovasc Surg, 2019 Feb 06; 158(1). PMID: 30718052    Free PMC article.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Rui Chen, Xiaoming Hou, Liping Yang, Da Zhao.
Thorac Cancer, 2019 Feb 09; 10(4). PMID: 30734504    Free PMC article.
Systematic Review.
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Kellie N Smith, Nicolas J Llosa, +38 authors, Franck Housseau.
J Immunother Cancer, 2019 Feb 13; 7(1). PMID: 30744692    Free PMC article.
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Norimichi Akiyama, Masato Karayama, +17 authors, Takafumi Suda.
Invest New Drugs, 2019 Feb 23; 37(3). PMID: 30790149
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Celeste Lebbé, Nicolas Meyer, +16 authors, Jacopo Pigozzo.
J Clin Oncol, 2019 Feb 28; 37(11). PMID: 30811280    Free PMC article.
Highly Cited.
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Zhijie Wang, Jianchun Duan, +27 authors, Jie Wang.
JAMA Oncol, 2019 Mar 01; 5(5). PMID: 30816954    Free PMC article.
Highly Cited.
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Shun Lu, Yongfeng Yu, Yi Yang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819828    Free PMC article.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, +6 authors, Roy S Herbst.
Clin Cancer Res, 2019 Mar 03; 25(15). PMID: 30824587    Free PMC article.
Highly Cited. Review.
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.
Young Kwang Chae, Jonathan F Anker, +5 authors, Jeffrey H Chuang.
Sci Rep, 2019 Mar 03; 9(1). PMID: 30824826    Free PMC article.
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M Rizk, Robyn D Gartrell, +4 authors, Yvonne M Saenger.
Hematol Oncol Clin North Am, 2019 Mar 06; 33(2). PMID: 30833001    Free PMC article.
Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen.
Nat Med, 2019 Mar 08; 25(3). PMID: 30842677    Free PMC article.
Highly Cited. Review.
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Yongshuai Jiang, Ming Chen, Hong Nie, Yuanyang Yuan.
Hum Vaccin Immunother, 2019 Mar 20; 15(5). PMID: 30888929    Free PMC article.
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
S Trebeschi, S G Drago, +15 authors, H J W L Aerts.
Ann Oncol, 2019 Mar 22; 30(6). PMID: 30895304    Free PMC article.
Highly Cited.
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Mark Yarchoan, Lee A Albacker, +8 authors, Elizabeth M Jaffee.
JCI Insight, 2019 Mar 22; 4(6). PMID: 30895946    Free PMC article.
Highly Cited.
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Biagio Ricciuti, Sasha Kravets, +7 authors, Mark M Awad.
J Immunother Cancer, 2019 Mar 30; 7(1). PMID: 30922388    Free PMC article.
Could the menagerie of the gut microbiome really cure cancer? Hope or hype.
Muhammad Bilal Abid.
J Immunother Cancer, 2019 Apr 04; 7(1). PMID: 30940203    Free PMC article.
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Re-I Chin, Kevin Chen, +6 authors, Aadel A Chaudhuri.
Mol Diagn Ther, 2019 Apr 04; 23(3). PMID: 30941670    Free PMC article.
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.
Dongxu Wang, Jianzhen Lin, +7 authors, Haitao Zhao.
J Hematol Oncol, 2019 Apr 25; 12(1). PMID: 31014381    Free PMC article.
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang, Shouhao Zhou, +16 authors, Michael L Wang.
JAMA Oncol, 2019 Apr 26; 5(7). PMID: 31021376    Free PMC article.
Highly Cited. Systematic Review.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Sonja Althammer, Tze Heng Tan, +14 authors, Keith E Steele.
J Immunother Cancer, 2019 May 08; 7(1). PMID: 31060602    Free PMC article.
Recent advances in triple negative breast cancer: the immunotherapy era.
Antonio Marra, Giulia Viale, Giuseppe Curigliano.
BMC Med, 2019 May 10; 17(1). PMID: 31068190    Free PMC article.
Highly Cited. Review.
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
Paolo A Ascierto, Paolo Bruzzi, +7 authors, Francesco Perrone.
J Transl Med, 2019 May 12; 17(1). PMID: 31077205    Free PMC article.
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
K Hastings, H A Yu, +28 authors, K Politi.
Ann Oncol, 2019 May 16; 30(8). PMID: 31086949    Free PMC article.
Highly Cited.
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Sehhoon Park, Je-Gun Joung, +10 authors, Jong-Mu Sun.
J Immunother Cancer, 2019 May 18; 7(1). PMID: 31097034    Free PMC article.
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Davide Bedognetti, Michele Ceccarelli, +53 authors, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
J Immunother Cancer, 2019 May 23; 7(1). PMID: 31113486    Free PMC article.
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Siwen Hu-Lieskovan, Aaron Lisberg, +16 authors, Edward B Garon.
Clin Cancer Res, 2019 May 23; 25(16). PMID: 31113840    Free PMC article.
Prognostic value of TIM-1 expression in human non-small-cell lung cancer.
Xiao Zheng, Kai Xu, +2 authors, Jingting Jiang.
J Transl Med, 2019 May 30; 17(1). PMID: 31138322    Free PMC article.
The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8+ T cells are important in maintaining normal pregnancy.
Songcun Wang, Fengrun Sun, +7 authors, Meirong Du.
Cell Death Dis, 2019 May 30; 10(6). PMID: 31138782    Free PMC article.
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Pengfei Zhao, Li Li, Xiaoyue Jiang, Qin Li.
J Hematol Oncol, 2019 Jun 04; 12(1). PMID: 31151482    Free PMC article.
Highly Cited. Review.
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Kazuki Takada, Mototsugu Shimokawa, +8 authors, Masaki Mori.
PLoS One, 2019 Jun 05; 14(6). PMID: 31163080    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
Mohammad Jafarnejad, Chang Gong, +6 authors, Aleksander S Popel.
AAPS J, 2019 Jun 27; 21(5). PMID: 31236847    Free PMC article.
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Han Chang, Ariella Sasson, +7 authors, Joseph Szustakowski.
Mol Diagn Ther, 2019 Jun 30; 23(4). PMID: 31250328    Free PMC article.
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
J Hematol Oncol, 2019 Jun 30; 12(1). PMID: 31253167    Free PMC article.
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Maria Saigi, Juan J Alburquerque-Bejar, Montse Sanchez-Cespedes.
Oncogene, 2019 Jun 30; 38(31). PMID: 31253869
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Tao Jiang, Jinpeng Shi, +13 authors, Caicun Zhou.
J Hematol Oncol, 2019 Jul 14; 12(1). PMID: 31299995    Free PMC article.
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Alexander Haragan, John K Field, +3 authors, John R Gosney.
Lung Cancer, 2019 Jul 20; 134. PMID: 31320000    Free PMC article.
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
Anna W Chalmers, Shiven Patel, +6 authors, Wallace Akerley.
Target Oncol, 2019 Jul 28; 14(4). PMID: 31346927
Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
Hao-Xiang Wu, Zi-Xian Wang, +2 authors, Rui-Hua Xu.
J Immunother Cancer, 2019 Aug 08; 7(1). PMID: 31387639    Free PMC article.
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Yoshihiko Sakata, Kodai Kawamura, +9 authors, Takuro Sakagami.
Thorac Cancer, 2019 Nov 05; 10(12). PMID: 31679185    Free PMC article.
Identifying successful biomarkers for patients with non-small-cell lung cancer.
Alex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna, Alfredo Addeo.
Lung Cancer Manag, 2019 Dec 07; 8(3). PMID: 31807145    Free PMC article.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.
Man Li, Anqi Lin, +5 authors, Linlang Guo.
Aging (Albany NY), 2020 Jan 22; 12(2). PMID: 31959735    Free PMC article.
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Valérie Janelle, Caroline Rulleau, +2 authors, Jean-Sébastien Delisle.
Front Immunol, 2020 Mar 11; 11. PMID: 32153583    Free PMC article.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Sun Min Lim, Min Hee Hong, Hye Ryun Kim.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158598    Free PMC article.
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Hanfei Guo, Rilan Bai, Jiuwei Cui.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093454    Free PMC article.
Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.
Peng Zhang, Xinxin Xiong, +8 authors, Pan Zheng.
Cancers (Basel), 2020 Jan 30; 12(2). PMID: 31991588    Free PMC article.
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment.
Ros Whelan, Eric Prince, Ahmed Gilani, Todd Hankinson.
J Clin Med, 2020 Feb 23; 9(2). PMID: 32075140    Free PMC article.
Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Qinghua Wang, Meiling Li, +5 authors, Kexin Chen.
Aging (Albany NY), 2020 Feb 25; 12(4). PMID: 32091408    Free PMC article.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Mari Aso, Yukihiro Toi, +15 authors, Shunichi Sugawara.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162801    Free PMC article.
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Michael Dougan.
Curr Gastroenterol Rep, 2020 Mar 19; 22(4). PMID: 32185493
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Hyojin Kim, Jin-Haeng Chung.
J Pathol Transl Med, 2019 May 03; 53(4). PMID: 31042863    Free PMC article.
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
Jun W Kim, Cesar P Marquez, +13 authors, E Alejandro Sweet-Cordero.
Nat Med, 2019 Nov 09; 25(11). PMID: 31700175    Free PMC article.
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.
Johannes Hofland, Gregory Kaltsas, Wouter W de Herder.
Endocr Rev, 2019 Sep 27; 41(2). PMID: 31555796    Free PMC article.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Lorenzo Galluzzi, Ilio Vitale, +51 authors, Francesco M Marincola.
J Immunother Cancer, 2020 Mar 27; 8(1). PMID: 32209603    Free PMC article.
The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy.
Cheng Yuan, Liyang Xiang, +8 authors, Conghua Xie.
Aging (Albany NY), 2020 Mar 14; 12(5). PMID: 32165590    Free PMC article.
Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples.
Joanne M Mankor, Marthe S Paats, +7 authors, Martijn P J K Lolkema.
Br J Cancer, 2020 Feb 26; 122(7). PMID: 32094484    Free PMC article.
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Luca Cantini, Raffit Hassan, Daniel H Sterman, Joachim G J V Aerts.
Front Oncol, 2020 Apr 01; 10. PMID: 32226777    Free PMC article.
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.
Livius Penter, Catherine J Wu.
J Clin Invest, 2020 Jan 28; 130(4). PMID: 31985488    Free PMC article.
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
Cancer Med, 2019 Jun 06; 8(8). PMID: 31165589    Free PMC article.
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, +16 authors, Marc Ladanyi.
Clin Cancer Res, 2019 Apr 28; 25(15). PMID: 31028088    Free PMC article.
Highly Cited.
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
D Isla, J de Castro, +5 authors, J M Trigo.
Clin Transl Oncol, 2019 Aug 02; 22(5). PMID: 31368078
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis, Michael Duruisseaux, Marie Brevet, Charles Dumontet.
Front Immunol, 2020 Apr 09; 11. PMID: 32265935    Free PMC article.
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Elisabeth M P Steeghs, Leonie I Kroeze, +10 authors, Astrid Eijkelenboom.
BMC Cancer, 2020 Apr 09; 20(1). PMID: 32264863    Free PMC article.
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Xin Chen, Xiaomin Song, Kang Li, Tong Zhang.
Front Immunol, 2019 Mar 14; 10. PMID: 30863404    Free PMC article.
Highly Cited. Review.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, +28 authors, MYSTIC Investigators.
JAMA Oncol, 2020 Apr 10; 6(5). PMID: 32271377    Free PMC article.
Mutation-Derived Neoantigens for Cancer Immunotherapy.
John C Castle, Mohamed Uduman, +2 authors, Jennifer S Buell.
Front Immunol, 2019 Aug 24; 10. PMID: 31440245    Free PMC article.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Kuniko Sunami, Hitoshi Ichikawa, +37 authors, Takashi Kohno.
Cancer Sci, 2019 Feb 12; 110(4). PMID: 30742731    Free PMC article.
Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Ting Sun, Qitai Zhao, +9 authors, Yi Zhang.
Cancer Med, 2019 Apr 27; 8(6). PMID: 31025554    Free PMC article.
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Rui Cao, Jie-Tao Ma, +6 authors, Cheng-Bo Han.
Cancer Med, 2019 Jul 13; 8(11). PMID: 31297962    Free PMC article.
Effective effectors: How T cells access and infiltrate the central nervous system.
Kendra L Congdon, Luis A Sanchez-Perez, John H Sampson.
Pharmacol Ther, 2018 Dec 18; 197. PMID: 30557632    Free PMC article.
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1.
Jing Zhao, Jian Huang.
Chin Med J (Engl), 2020 Feb 28; 133(7). PMID: 32106121    Free PMC article.
Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing.
Hidenori Kage, Shinji Kohsaka, +10 authors, Takahide Nagase.
Cancer Sci, 2019 Jun 22; 110(8). PMID: 31222846    Free PMC article.
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Marine Leclerc, Laura Mezquita, +4 authors, Fathia Mami-Chouaib.
Front Immunol, 2019 Jul 25; 10. PMID: 31333652    Free PMC article.
Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients.
Eric C Ko, Lorenzo Galluzzi.
Oncoimmunology, 2019 Aug 16; 8(8). PMID: 31413913    Free PMC article.
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Jeffrey C Thompson, Wei-Ting Hwang, +9 authors, Steven M Albelda.
Lung Cancer, 2019 Nov 05; 139. PMID: 31683225    Free PMC article.
Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma.
Qiyun Ou, Yunfang Yu, +11 authors, Baoming Luo.
Ann Transl Med, 2020 Apr 21; 8(5). PMID: 32309377    Free PMC article.
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Jie Liu, Chengming Li, +2 authors, Xue Meng.
Oncoimmunology, 2020 Apr 22; 9(1). PMID: 32313723    Free PMC article.
Systematic Review.
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
Silvia Pesce, Marco Greppi, +5 authors, Emanuela Marcenaro.
Front Immunol, 2019 Jun 20; 10. PMID: 31214193    Free PMC article.
Highly Cited. Review.
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Diana M Merino, Lisa M McShane, +31 authors, TMB Harmonization Consortium.
J Immunother Cancer, 2020 Mar 29; 8(1). PMID: 32217756    Free PMC article.
Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
Nicholas Bevins, Shulei Sun, +2 authors, Sarah S Murray.
J Immunother Cancer, 2020 Mar 29; 8(1). PMID: 32217764    Free PMC article.
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Laurent Mhanna, Nicolas Guibert, Julie Milia, Julien Mazieres.
Curr Treat Options Oncol, 2019 Jun 07; 20(7). PMID: 31172347    Free PMC article.
Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Ping Mei, Konstantin Shilo, +3 authors, Zaibo Li.
Cancer Cytopathol, 2019 Apr 27; 127(7). PMID: 31025831    Free PMC article.
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Chih-Hsi Scott Kuo, Chin-Chou Wang, +8 authors, Cheng-Ta Yang.
Thorac Cancer, 2019 Apr 06; 10(5). PMID: 30950239    Free PMC article.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Peng Song, Xiaoxia Cui, +14 authors, Li Zhang.
Thorac Cancer, 2019 Apr 25; 10(5). PMID: 31016875    Free PMC article.
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Dwight H Owen, Terence M Williams, +7 authors, Gregory A Otterson.
Lung Cancer, 2019 Jul 20; 134. PMID: 31319977    Free PMC article.
Immune-based therapies for hepatocellular carcinoma.
David J Pinato, Nadia Guerra, +8 authors, Lorenza Rimassa.
Oncogene, 2020 Mar 12; 39(18). PMID: 32157213    Free PMC article.
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
Menno Tamminga, Sanne de Wit, +4 authors, Harry J M Groen.
J Immunother Cancer, 2019 Jul 12; 7(1). PMID: 31291995    Free PMC article.
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella.
J Immunother Cancer, 2019 Jul 17; 7(1). PMID: 31307554    Free PMC article.
Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Kazutoshi Komiya, Tomomi Nakamura, +5 authors, Naoko Sueoka-Aragane.
Thorac Cancer, 2019 Jul 23; 10(9). PMID: 31328416    Free PMC article.
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.
Kohei Shitara, Satoshi Ueha, +18 authors, Toshihiko Doi.
J Immunother Cancer, 2019 Jul 26; 7(1). PMID: 31340866    Free PMC article.
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
A Pavan, I Attili, +3 authors, L Bonanno.
J Immunother Cancer, 2019 Aug 07; 7(1). PMID: 31383005    Free PMC article.
Current issues and perspectives in PD-1 blockade cancer immunotherapy.
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo.
Int J Clin Oncol, 2020 Jan 05; 25(5). PMID: 31900651    Free PMC article.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Carminia M Della Corte, Triparna Sen, +21 authors, Lauren A Byers.
J Thorac Oncol, 2020 Feb 19; 15(5). PMID: 32068166    Free PMC article.
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.
Simon Papillon-Cavanagh, Parul Doshi, +2 authors, Alice M Walsh.
ESMO Open, 2020 Apr 22; 5(2). PMID: 32312757    Free PMC article.
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
Xiangyu Su, Jing Zhang, +2 authors, Cailian Wang.
Onco Targets Ther, 2020 May 06; 13. PMID: 32368090    Free PMC article.
Immuno-oncology-the new paradigm of lung cancer treatment.
D E Dawe, C H Harlos, R A Juergens.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368177    Free PMC article.
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
Yang Liu, Pan Zheng.
Trends Pharmacol Sci, 2019 Dec 15; 41(1). PMID: 31836191    Free PMC article.
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Matthew Kyle Labriola, Jason Zhu, +9 authors, Tian Zhang.
J Immunother Cancer, 2020 Mar 30; 8(1). PMID: 32221016    Free PMC article.
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Alexander J Neuwelt, Abigail K Kimball, +11 authors, Eric T Clambey.
J Immunother Cancer, 2020 Apr 22; 8(1). PMID: 32312906    Free PMC article.
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Eric X Chen, Derek J Jonker, +18 authors, Chris J O'Callaghan.
JAMA Oncol, 2020 May 08; 6(6). PMID: 32379280    Free PMC article.
Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges.
Sijia Ren, Chunguo Wang, Jianfei Shen, Chengchu Zhu.
J Thorac Dis, 2020 May 13; 12(4). PMID: 32395299    Free PMC article.
Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort.
Yuan Li, Zuhua Chen, Long Wu, Weiping Tao.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395490    Free PMC article.
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Alberto Puccini, Francesca Battaglin, +2 authors, Mohamed E Salem.
J Immunother Cancer, 2020 May 13; 8(1). PMID: 32393474    Free PMC article.
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, +18 authors, Erica L Carpenter.
Clin Cancer Res, 2020 Feb 28; 26(10). PMID: 32102950    Free PMC article.
Contribution of Macrophages and T Cells in Skeletal Metastasis.
Veronica Mendoza-Reinoso, Laurie K McCauley, Pierrick G J Fournier.
Cancers (Basel), 2020 Apr 25; 12(4). PMID: 32326073    Free PMC article.
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.
Ping Mei, C Eric Freitag, +3 authors, Zaibo Li.
Diagn Pathol, 2020 May 13; 15(1). PMID: 32393302    Free PMC article.
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Pengfei Cui, Di Huang, +9 authors, Yi Hu.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426052    Free PMC article.
RAD51B Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer.
Inês Maria Guerreiro, Daniela Barros-Silva, +8 authors, Carmen Jerónimo.
J Clin Med, 2020 Apr 08; 9(4). PMID: 32252414    Free PMC article.
The emerging role of epigenetic therapeutics in immuno-oncology.
Michael J Topper, Michelle Vaz, +2 authors, Stephen B Baylin.
Nat Rev Clin Oncol, 2019 Sep 25; 17(2). PMID: 31548600    Free PMC article.
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, +11 authors, Carol Aghajanian.
J Clin Oncol, 2020 Apr 11; 38(16). PMID: 32275468    Free PMC article.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
Sandra P D'Angelo, Shailender Bhatia, +15 authors, Paul T Nghiem.
J Immunother Cancer, 2020 May 18; 8(1). PMID: 32414862    Free PMC article.
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Yiding Li, Zhiming Wang, +16 authors, Lifan Xu.
Front Immunol, 2020 Jun 02; 11. PMID: 32477338    Free PMC article.
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Romualdo Barroso-Sousa, Tanya E Keenan, +18 authors, Sara M Tolaney.
Clin Cancer Res, 2020 Feb 06; 26(11). PMID: 32019858    Free PMC article.
Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Lucas Ferrari de Andrade, Sushil Kumar, +6 authors, Kai W Wucherpfennig.
Cancer Immunol Res, 2020 Mar 27; 8(6). PMID: 32209637    Free PMC article.
Review of precision cancer medicine: Evolution of the treatment paradigm.
Apostolia M Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock.
Cancer Treat Rev, 2020 Apr 07; 86. PMID: 32251926    Free PMC article.
Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
B Melosky, S Banerji, +5 authors, P Cheema.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489263    Free PMC article.
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, +7 authors, F López-Ríos.
Clin Transl Oncol, 2019 Oct 11; 22(7). PMID: 31598903    Free PMC article.
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Laura S Graham, Bruce Montgomery, +6 authors, Michael T Schweizer.
PLoS One, 2020 May 27; 15(5). PMID: 32453797    Free PMC article.
Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
Sunhee Chang, Jae Young Hur, +2 authors, Wan Seop Kim.
J Pathol Transl Med, 2020 May 29; 54(3). PMID: 32460474    Free PMC article.
Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.
Wenfeng Fang, Yuxiang Ma, +11 authors, Li Zhang.
Clin Transl Med, 2020 Jun 09; 10(1). PMID: 32508057    Free PMC article.
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Fotios Loupakis, Ilaria Depetris, +23 authors, Matteo Fassan.
Oncologist, 2020 Jan 23; 25(6). PMID: 31967692    Free PMC article.
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
Kengo Kuriyama, Tamami Higuchi, +13 authors, Hiroshi Saeki.
Cancer Sci, 2020 Apr 18; 111(6). PMID: 32302443    Free PMC article.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.
Diego A Lema, Ewa Jankowska-Gan, +2 authors, Ticiana Leal.
J Immunother Cancer, 2020 Jun 13; 8(1). PMID: 32527929    Free PMC article.
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Matthew D Hellmann, Barzin Y Nabet, +32 authors, Maximilian Diehn.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046999    Free PMC article.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Keisuke Onoi, Yusuke Chihara, +6 authors, Koichi Takayama.
J Clin Med, 2020 May 10; 9(5). PMID: 32384677    Free PMC article.
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.
Yu Chen, Yanqing Pei, +3 authors, Xiangjiao Meng.
Front Immunol, 2020 Jun 18; 11. PMID: 32547566    Free PMC article.
Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment.
Joanna P MacEwan, Komal Gupte-Singh, Lauren M Zhao, Karen L Reckamp.
MDM Policy Pract, 2020 Jun 18; 5(1). PMID: 32548305    Free PMC article.
Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy.
Gang Chen, Lin Wang, +3 authors, Xindong Zhang.
Oncol Lett, 2020 Jun 23; 20(1). PMID: 32565977    Free PMC article.
Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications.
Anwaar Saeed, Mohamed E Salem.
Ann Transl Med, 2020 Jun 23; 8(9). PMID: 32566602    Free PMC article.
Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages.
Emmanuelle Alaluf, Benoît Vokaer, +8 authors, Stanislas Goriely.
JCI Insight, 2020 May 06; 5(11). PMID: 32369450    Free PMC article.
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Katsuo Usuda, Yo Niida, +5 authors, Hidetaka Uramoto.
Front Oncol, 2020 Jun 26; 10. PMID: 32582526    Free PMC article.
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin, Robin Guo, +18 authors, Alexander Drilon.
JCO Precis Oncol, 2019 Jun 14; 3. PMID: 31192313    Free PMC article.
Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature.
Carlos Salinas, Alex Renner, +2 authors, Mauricio Burotto.
Case Rep Oncol, 2020 Jul 01; 13(2). PMID: 32595473    Free PMC article.
Brain immunology and immunotherapy in brain tumours.
John H Sampson, Michael D Gunn, Peter E Fecci, David M Ashley.
Nat Rev Cancer, 2019 Dec 07; 20(1). PMID: 31806885    Free PMC article.
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, +10 authors, Jean-François Emile.
J Immunother Cancer, 2020 Jun 26; 8(1). PMID: 32581058    Free PMC article.
Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
Yuhui Ma, Quan Li, +10 authors, Yongchun Zhou.
Onco Targets Ther, 2020 Jul 02; 13. PMID: 32606739    Free PMC article.
Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Yan'e Liu, Jie Zhang, +3 authors, Baoshan Cao.
Thorac Cancer, 2020 May 08; 11(7). PMID: 32379397    Free PMC article.
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai, De-Hua Wu, +11 authors, Zhong-Yi Dong.
J Immunother Cancer, 2020 Jul 02; 8(1). PMID: 32606052    Free PMC article.
Role of DNA repair defects in predicting immunotherapy response.
Jing Zhang, David J H Shih, Shiaw-Yih Lin.
Biomark Res, 2020 Jul 03; 8. PMID: 32612833    Free PMC article.
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.
Daniel J McGrail, Jeannine Garnett, +20 authors, Shiaw-Yih Lin.
Cancer Cell, 2020 Feb 29; 37(3). PMID: 32109374    Free PMC article.
Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
Akira Ono, Yukihiro Terada, +17 authors, Toshiaki Takahashi.
Cancer Med, 2020 May 14; 9(13). PMID: 32400056    Free PMC article.
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.
J A Kyte, N K Andresen, +4 authors, B Naume.
J Transl Med, 2020 Jul 06; 18(1). PMID: 32620163    Free PMC article.
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
Wenjie You, Bin Shang, +3 authors, Shujuan Jiang.
Oncol Rep, 2020 Jul 07; 44(2). PMID: 32627031    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
Bingxi He, Di Dong, +8 authors, Chang Chen.
J Immunother Cancer, 2020 Jul 09; 8(2). PMID: 32636239    Free PMC article.
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.
Ana I Velazquez, Caroline E McCoach.
J Thorac Dis, 2020 Jul 10; 12(5). PMID: 32642202    Free PMC article.
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
Carina Heydt, Jan Rehker, +8 authors, Sabine Merkelbach-Bruse.
Sci Rep, 2020 Jul 11; 10(1). PMID: 32647293    Free PMC article.
The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination.
Rui Shi, Yan Chai, +7 authors, Jinghua Yan.
Signal Transduct Target Ther, 2020 Apr 17; 5(1). PMID: 32296041    Free PMC article.
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Stefanie Schatz, Markus Falk, +12 authors, Lukas C Heukamp.
Cancers (Basel), 2020 Jul 01; 12(6). PMID: 32599951    Free PMC article.
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
Casey Quinn, Louis P Garrison, +8 authors, Elise Wu.
J Immunother Cancer, 2020 Jul 15; 8(2). PMID: 32661115    Free PMC article.
Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma.
Qing-Jiang Yu, Yi-Zhi Liang, Xiao-Ping Mei, Tai-Yong Fang.
EXCLI J, 2020 Jul 16; 19. PMID: 32665773    Free PMC article.
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.
Robert J Walsh, Ross A Soo.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670423    Free PMC article.
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Eileen M O'Reilly, Do-Youn Oh, +11 authors, Philip Agop Philip.
JAMA Oncol, 2019 Jul 19; 5(10). PMID: 31318392    Free PMC article.
Highly Cited.
Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Kyle G Mitchell, Marcelo V Negrao, +14 authors, Boris Sepesi.
Ann Thorac Surg, 2019 Sep 25; 109(2). PMID: 31550464    Free PMC article.
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.
Yoshinobu Ichiki, Takashi Fukuyama, Kozo Nakanishi.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676343    Free PMC article.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Dominique Arpin, Marie-Christine Charpentier, +23 authors, Diane Damotte.
Ther Adv Med Oncol, 2020 Jul 21; 12. PMID: 32684990    Free PMC article.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei.
Cancer, 2019 Nov 07; 126(2). PMID: 31691957    Free PMC article.
Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.
Syed H Zaidi, Tabitha A Harrison, +73 authors, Ulrike Peters.
Nat Commun, 2020 Jul 21; 11(1). PMID: 32686686    Free PMC article.
Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?
Megan Greally, Geoffrey Y Ku.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746176    Free PMC article.
Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology.
Ya-Qin Wang, Lei Chen, +15 authors, Jun Ma.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690665    Free PMC article.
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Sjoerd T T Schetters, Ernesto Rodriguez, +5 authors, Yvette Van Kooyk.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690667    Free PMC article.
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer.
Montreh Tavakkoli, Cy R Wilkins, Jodi V Mones, Michael J Mauro.
Front Oncol, 2019 May 14; 9. PMID: 31080780    Free PMC article.
Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok.
Front Immunol, 2020 Aug 01; 11. PMID: 32733486    Free PMC article.
Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?
Michal Sternschuss, Nir Peled, +6 authors, Alona Zer.
Thorac Cancer, 2020 Jun 18; 11(8). PMID: 32548905    Free PMC article.
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.
So Yeon Kim, Balazs Halmos.
Lung Cancer Manag, 2020 Aug 11; 9(3). PMID: 32774467    Free PMC article.
Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer.
Rahul Ladwa, Kate E Roberts, +3 authors, Kenneth Miles.
Lung Cancer Manag, 2020 Aug 11; 9(3). PMID: 32774469    Free PMC article.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Tingting Liu, Bo Jin, +4 authors, Guang Li.
Ther Adv Med Oncol, 2020 Aug 11; 12. PMID: 32774474    Free PMC article.
Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
Yongping Liu, Lin Chen, +5 authors, Yang Ling.
Oncol Lett, 2020 Aug 11; 20(4). PMID: 32774500    Free PMC article.
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Yanhui Chen, Yating Wang, +5 authors, Henghui Zhang.
Exp Hematol Oncol, 2020 Aug 11; 9. PMID: 32775040    Free PMC article.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
Anna-Larissa Nadia Niemeijer, Sara Sahba, +3 authors, Erik Thunnissen.
Br J Cancer, 2020 May 21; 123(3). PMID: 32433601    Free PMC article.
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.
Jorge García-González, Juan Ruiz-Bañobre, +12 authors, Luis León-Mateos.
J Clin Med, 2020 Jul 09; 9(7). PMID: 32635291    Free PMC article.
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Alexandre Perrier, Audrey Didelot, +2 authors, Simon Garinet.
Biomolecules, 2020 Jul 28; 10(7). PMID: 32708698    Free PMC article.
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Kevin Litchfield, James L Reading, +17 authors, Charles Swanton.
Nat Commun, 2020 Aug 01; 11(1). PMID: 32733040    Free PMC article.
Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
Xiao-Dong Jiao, Xiao-Chun Zhang, +16 authors, Yuan-Sheng Zang.
Ann Transl Med, 2020 Aug 15; 8(14). PMID: 32793704    Free PMC article.
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Elisa Aquilanti, Priscilla K Brastianos.
Neurosurgery, 2020 Apr 18; 87(3). PMID: 32302389    Free PMC article.
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Yuanyuan Zhang, Zemin Zhang.
Cell Mol Immunol, 2020 Jul 03; 17(8). PMID: 32612154    Free PMC article.
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Chris Dickhoff, Suresh Senan, +13 authors, Idris Bahce.
BMC Cancer, 2020 Aug 17; 20(1). PMID: 32795284    Free PMC article.
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer.
Wei Liu, Lei Zhang, +6 authors, Jianhui Cai.
Onco Targets Ther, 2020 Aug 18; 13. PMID: 32801752    Free PMC article.
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Jiyun Lee, Jong-Mu Sun, +3 authors, Myung-Ju Ahn.
J Thorac Dis, 2020 Aug 18; 12(7). PMID: 32802459    Free PMC article.
Value of circular RNA 0007385 in disease monitoring and prognosis estimation in non-small-cell lung cancer patients.
Yijian Lin, Weiming Su, Guocui Lan.
J Clin Lab Anal, 2020 Jul 16; 34(8). PMID: 32666646    Free PMC article.
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.
Zhihao Lu, Huan Chen, +14 authors, Lin Shen.
J Immunother Cancer, 2020 Aug 15; 8(2). PMID: 32792358    Free PMC article.
Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential.
Stina George Fernandes, Rebecca Dsouza, +5 authors, Ekta Khattar.
Cancers (Basel), 2020 Jul 18; 12(7). PMID: 32674474    Free PMC article.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?
Nagio Takigawa, Nobuaki Ochi, +7 authors, Hiromichi Yamane.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32708291    Free PMC article.
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Alberto Carretero-González, David Lora, +6 authors, Guillermo de Velasco.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32709062    Free PMC article.
Progress in Neoantigen Targeted Cancer Immunotherapies.
Xue-Jiao Han, Xue-Lei Ma, +3 authors, Xia-Wei Wei.
Front Cell Dev Biol, 2020 Aug 28; 8. PMID: 32850843    Free PMC article.
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
Vishal Navani, Moira C Graves, Nikola A Bowden, Andre Van Der Westhuizen.
Br J Clin Pharmacol, 2020 May 10; 86(9). PMID: 32384184    Free PMC article.
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Byung Woog Kang, Ian Chau.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817133    Free PMC article.
Rational design of anti-GITR-based combination immunotherapy.
Roberta Zappasodi, Cynthia Sirard, +16 authors, Taha Merghoub.
Nat Med, 2019 May 01; 25(5). PMID: 31036879    Free PMC article.
Highly Cited.
CD47 prevents the elimination of diseased fibroblasts in scleroderma.
Tristan Lerbs, Lu Cui, +7 authors, Gerlinde Wernig.
JCI Insight, 2020 Aug 21; 5(16). PMID: 32814713    Free PMC article.
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors.
Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui.
Biomark Res, 2020 Aug 31; 8. PMID: 32864131    Free PMC article.
[Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer].
Huanlan Sa, Kewei Ma, Yong Gao, Deqiang Wang.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196372    Free PMC article.
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Sixuan Wu, Chunhong Hu, +2 authors, Ping Liu.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315783    Free PMC article.
Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions.
Erkki-Ville Wirta, Säde Szeto, +5 authors, Toni T Seppälä.
Cancers (Basel), 2020 Jul 29; 12(8). PMID: 32718028    Free PMC article.
Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Chaoqi Zhang, Guochao Zhang, +6 authors, Jie He.
EBioMedicine, 2020 Aug 28; 59. PMID: 32853987    Free PMC article.
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.
Evan M Fernandez, Kenneth Eng, +12 authors, Wei Song.
JCO Precis Oncol, 2019 Sep 03; 3. PMID: 31475242    Free PMC article.
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Alessandra Raimondi, Pierangela Sepe, +7 authors, Giuseppe Procopio.
Front Oncol, 2020 Sep 10; 10. PMID: 32903369    Free PMC article.
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Michael A Postow, Scott D Chasalow, +4 authors, Jedd D Wolchok.
Melanoma Res, 2019 Aug 20; 30(1). PMID: 31425479    Free PMC article.
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Xinru Chen, Zhonghan Zhang, +10 authors, Li Zhang.
J Immunother Cancer, 2020 Aug 31; 8(2). PMID: 32863271    Free PMC article.
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
Norah J Shire, Alyssa B Klein, +6 authors, Naiyer A Rizvi.
PLoS One, 2020 Sep 04; 15(9). PMID: 32881920    Free PMC article.
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Gino K In, Kelsey Poorman, +12 authors, Ari Vanderwalde.
Oncotarget, 2020 Sep 12; 11(33). PMID: 32913556    Free PMC article.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Gernot Wagner, Hannah Karolina Stollenwerk, +3 authors, Josef Singer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923134    Free PMC article.
Systematic Review.
A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.
Ling Peng, Bao-Dong Qin, +5 authors, Li-Ping Xie.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923143    Free PMC article.
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.
Jingyu Cao, Jing Hu, +16 authors, Haitao Zhao.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923885    Free PMC article.
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.
Michael Bitzer, Leonie Ostermann, +15 authors, Nisar P Malek.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923905    Free PMC article.
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Changhee Park, Kwon Joong Na, +14 authors, Dae Seog Heo.
Theranostics, 2020 Sep 16; 10(23). PMID: 32929383    Free PMC article.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Trial watch: TLR3 agonists in cancer therapy.
Julie Le Naour, Lorenzo Galluzzi, +2 authors, Erika Vacchelli.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934877    Free PMC article.
Trial watch: STING agonists in cancer therapy.
Julie Le Naour, Laurence Zitvogel, +2 authors, Guido Kroemer.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934881    Free PMC article.
Trial watch: IDO inhibitors in cancer therapy.
Julie Le Naour, Lorenzo Galluzzi, +2 authors, Erika Vacchelli.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934882    Free PMC article.
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Minyu Wang, Sen Wang, Joseph A Trapani, Paul J Neeson.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944371    Free PMC article.
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Xiaoyang Zhai, Jian Zhang, +4 authors, Hui Zhu.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944393    Free PMC article.
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.
Arsen Osipov, Su Jin Lim, +6 authors, Mark Yarchoan.
Clin Cancer Res, 2020 Jun 27; 26(18). PMID: 32586938    Free PMC article.
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives.
Sabine Wessels, Thomas Muley, +17 authors, Marc A Schneider.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953480    Free PMC article.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Young Kwang Chae, Won Bin Kim, +11 authors, Pedro Viveiros.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953481    Free PMC article.
A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Siyu Peng, Ariel Fangting Ying, Bee Choo Tai, Ross Andrew Soo.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953491    Free PMC article.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang, Ming Li, +7 authors, Lijie Tan.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953506    Free PMC article.
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.
Antonino Grassadonia, Isabella Sperduti, +11 authors, Nicola Tinari.
J Clin Med, 2018 Dec 14; 7(12). PMID: 30545122    Free PMC article.
The clinical promise of immunotherapy in triple-negative breast cancer.
Praveen Vikas, Nicholas Borcherding, Weizhou Zhang.
Cancer Manag Res, 2018 Dec 24; 10. PMID: 30573992    Free PMC article.
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.
Federico Pio Fabrizio, Domenico Trombetta, +3 authors, Lucia Anna Muscarella.
Ther Adv Med Oncol, 2018 Dec 24; 10. PMID: 30574211    Free PMC article.
ASCO 2018 NSCLC highlights-combination therapy is key.
Gabriele Gamerith, Florian Kocher, Jakob Rudzki, Andreas Pircher.
Memo, 2019 Jan 01; 11(4). PMID: 30595752    Free PMC article.
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.
Bryan C Ulrich, Nicolas Guibert.
Ann Transl Med, 2019 Jan 08; 6(Suppl 1). PMID: 30613623    Free PMC article.
Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?
Mariam Alexander, Jose Galeas, Haiying Cheng.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631537    Free PMC article.
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Bairavi Shankar, Jarushka Naidoo.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631548    Free PMC article.
Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?
Dwight H Owen, Gregory A Otterson.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631557    Free PMC article.
Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing.
Yuki Matsumura, Yuki Owada-Ozaki, Hiroyuki Suzuki.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631578    Free PMC article.
Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.
Maiko Takeda, Takahiko Kasai, +13 authors, Shinji Atagi.
Clin Med Insights Oncol, 2019 Jan 24; 13. PMID: 30670923    Free PMC article.
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer.
Tiffany Seto, Danny Sam, Minggui Pan.
Med Sci (Basel), 2019 Jan 27; 7(2). PMID: 30678257    Free PMC article.
Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.
Lars Michel, Tienush Rassaf, Matthias Totzeck.
J Thorac Dis, 2019 Feb 01; 10(Suppl 35). PMID: 30701097    Free PMC article.
Highly Cited. Review.
The combination strategies will be ready the right first-line choice for squamous lung cancer patients?
Cesare Gridelli, Francesca Casaluce.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705852    Free PMC article.
Tumor mutational burden as predictive factor of response to immunotherapy.
Maria Gonzalez-Cao, Santiago Viteri, +3 authors, Rafael Rosell.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705855    Free PMC article.
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Virginie Lemiale, Anne-Pascale Meert, +5 authors, Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH).
Ann Intensive Care, 2019 Feb 02; 9(1). PMID: 30707321    Free PMC article.
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.
Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli.
Cancers (Basel), 2019 Feb 13; 11(2). PMID: 30744168    Free PMC article.
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients.
Shi Zhou, Samrat Khanal, Haijun Zhang.
Ther Clin Risk Manag, 2019 Feb 19; 15. PMID: 30774357    Free PMC article.
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.
Léa Berland, Simon Heeke, +11 authors, Marius Ilié.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775030    Free PMC article.
Update on emerging biomarkers in lung cancer.
Eric H Bernicker, Timothy Craig Allen, Phillip T Cagle.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775031    Free PMC article.
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.
Guillaume Herbreteau, Audrey Vallée, +3 authors, Marc G Denis.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775034    Free PMC article.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Jie Li, Qi He, +3 authors, Minjie Guan.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863172    Free PMC article.
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.
Concetta Elisa Onesti, Pierre Frères, Guy Jerusalem.
J Thorac Dis, 2019 Mar 14; 11(1). PMID: 30863564    Free PMC article.
Are lung adenocarcinoma mutations shaping the immune microenvironment?
Philippe Rochigneux, Edward B Garon.
Transl Cancer Res, 2019 Mar 25; 7(Suppl 7). PMID: 30906701    Free PMC article.
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing.
Jingsi Dong, Bingjie Li, +2 authors, Depei Huang.
Front Pharmacol, 2019 Apr 02; 10. PMID: 30930778    Free PMC article.
Highly Cited. Review.
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
Jose M Pacheco, D Ross Camidge, Robert C Doebele, Erin Schenk.
Front Oncol, 2019 Apr 16; 9. PMID: 30984621    Free PMC article.
Highly Cited. Review.
The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Kenichi Suda.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997217    Free PMC article.
KEYNOTE-024: goodbye to chemotherapy?
Rossana Berardi.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997239    Free PMC article.
The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition.
Melissa A Lumish, Mark A Anderson, +4 authors, Meghan J Mooradian.
JAAD Case Rep, 2019 Apr 23; 5(4). PMID: 31008173    Free PMC article.
Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response.
Iwona Kwiecien, Tomasz Skirecki, +2 authors, Joanna Domagala-Kulawik.
Cancers (Basel), 2019 Apr 24; 11(4). PMID: 31010080    Free PMC article.
The Discovery of Biomarkers in Cancer Immunotherapy.
Anil P George, Timothy M Kuzel, Yi Zhang, Bin Zhang.
Comput Struct Biotechnol J, 2019 Apr 24; 17. PMID: 31011407    Free PMC article.
Second-line treatment options in hepatocellular carcinoma.
Donatella Marino, Clizia Zichi, +2 authors, Massimo Di Maio.
Drugs Context, 2019 Apr 27; 8. PMID: 31024634    Free PMC article.
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key.
Robert Pirker.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032327    Free PMC article.
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Sebastian Chrétien, Ioannis Zerdes, +2 authors, Theodoros Foukakis.
Cancers (Basel), 2019 May 08; 11(5). PMID: 31060337    Free PMC article.
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Caiqing Zhang, Shuisheng Zhang, +5 authors, Yuan Tian.
Cancer Manag Res, 2019 May 24; 11. PMID: 31118808    Free PMC article.
And They Said It Couldn't Be Done: Predicting Known Driver Mutations From H&E Slides.
Michael C Montalto, Robin Edwards.
J Pathol Inform, 2019 Jun 01; 10. PMID: 31149368    Free PMC article.
Liquid biopsy for lung cancer immunotherapy.
Liang-Liang Cai, Jie Wang.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186680    Free PMC article.
Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis.
Yi Liu, Sijing Zhou, +5 authors, Ran Wang.
Cancer Manag Res, 2019 Jun 14; 11. PMID: 31191023    Free PMC article.
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
Diego De Goycoechea, Gregoire Stalder, Filipe Martins, Michel A Duchosal.
J Oncol, 2019 Jun 18; 2019. PMID: 31205470    Free PMC article.
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
Veronica Mollica, Vincenzo Di Nunno, +8 authors, Francesco Massari.
Cancers (Basel), 2019 Jun 19; 11(6). PMID: 31207938    Free PMC article.
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date.
Jordi Remon, Laura Esteller, Álvaro Taus.
Cancer Manag Res, 2019 Jun 20; 11. PMID: 31213908    Free PMC article.
Highlights of thoracic oncology from the 2018 ERS International Congress.
Polyxeni Ntontsi, Clementine Bostantzoglou, Torsten Gerriet Blum.
ERJ Open Res, 2019 Jun 21; 5(2). PMID: 31218220    Free PMC article.
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Jon H Chung, Ninad Dewal, +15 authors, Neeraj Agarwal.
JCO Precis Oncol, 2019 Jun 21; 3. PMID: 31218271    Free PMC article.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports.
Fadi Nasr, Ahmad Al Ghoche, +4 authors, Moussa Riachi.
Case Rep Oncol, 2019 Jun 28; 12(2). PMID: 31244645    Free PMC article.
Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis.
Jiaxin Zhu, Tiantian Zhang, +5 authors, Jie Jiang.
Front Pharmacol, 2019 Jul 02; 10. PMID: 31258479    Free PMC article.
Systematic Review.
Possible Biomarkers for Cancer Immunotherapy.
Takehiro Otoshi, Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura.
Cancers (Basel), 2019 Jul 07; 11(7). PMID: 31277279    Free PMC article.
Immune-Related Adverse Events: A Case-Based Approach.
Caoilfhionn Connolly, Kalindi Bambhania, Jarushka Naidoo.
Front Oncol, 2019 Jul 12; 9. PMID: 31293970    Free PMC article.
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Florian Huemer, David Lang, +7 authors, Richard Greil.
J Clin Med, 2019 Jul 13; 8(7). PMID: 31295966    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.
Gabrielle Planes-Laine, Philippe Rochigneux, +4 authors, Anthony Gonçalves.
Cancers (Basel), 2019 Jul 25; 11(7). PMID: 31336685    Free PMC article.
Highly Cited. Review.
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.
Ziqing Chen, Ying Yang, Lisa L Liu, Andreas Lundqvist.
Cancers (Basel), 2019 Jul 26; 11(7). PMID: 31340613    Free PMC article.
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.
Orgilmaa Regzedmaa, Hongbing Zhang, Hongyu Liu, Jun Chen.
Onco Targets Ther, 2019 Jul 30; 12. PMID: 31354294    Free PMC article.
Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report.
Weiwei Kong, Jia Wei, +6 authors, Baorui Liu.
Onco Targets Ther, 2019 Jul 31; 12. PMID: 31360065    Free PMC article.
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey.
Jeffrey P Gregg, Tianhong Li, Ken Y Yoneda.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367542    Free PMC article.
Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer.
Vincent K Lam, Jianjun Zhang.
J Thorac Dis, 2019 Aug 03; 11(6). PMID: 31372254    Free PMC article.
Tumor mutation burden: from comprehensive mutational screening to the clinic.
Francesca Galuppini, Carlo Alberto Dal Pozzo, +3 authors, Raffaele Baffa.
Cancer Cell Int, 2019 Aug 14; 19. PMID: 31406485    Free PMC article.
The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.
Giuseppe Luigi Banna, Timothée Olivier, +4 authors, Alfredo Addeo.
Front Med (Lausanne), 2019 Aug 17; 6. PMID: 31417906    Free PMC article.
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Tingting Liu, Silu Ding, +3 authors, Guang Li.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463119    Free PMC article.
Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma.
Narayanan Sadagopan, Craig Devoe.
Case Rep Oncol Med, 2019 Aug 31; 2019. PMID: 31467751    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Liquid biopsy for lung cancers: an update on recent developments.
Alberto E Revelo, Alvaro Martin, +4 authors, Gregory Otterson.
Ann Transl Med, 2019 Sep 14; 7(15). PMID: 31516895    Free PMC article.
The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer.
Udit Chaddha, D Kyle Hogarth, Septimiu Murgu.
Ann Transl Med, 2019 Sep 14; 7(15). PMID: 31516897    Free PMC article.
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer.
Qin Feng, Bin He.
Front Oncol, 2019 Sep 26; 9. PMID: 31552182    Free PMC article.
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC).
Greg Durm, Nasser Hanna.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555527    Free PMC article.
Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease.
Haruki Kobayashi, Masakuni Serizawa, +12 authors, Toshiaki Takahashi.
Respirology, 2019 Nov 07; 25(8). PMID: 31694070    Free PMC article.
Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.
David Shao-Peng Tan, Daniel Shao-Weng Tan, +4 authors, William Ying Khee Hwang.
Asia Pac J Clin Oncol, 2020 Apr 18; 16(4). PMID: 32301274    Free PMC article.
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Joshua E Reuss, Valsamo Anagnostou, +29 authors, Patrick M Forde.
J Immunother Cancer, 2020 Sep 16; 8(2). PMID: 32929052    Free PMC article.
New biomarkers for checkpoint inhibitor therapy.
Nikki Burdett, Jayesh Desai.
ESMO Open, 2020 Sep 17; 5(Suppl 1). PMID: 32933940    Free PMC article.
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li Li, Gang Li, +8 authors, Yao-Zhong Wu.
Sci Rep, 2020 Sep 25; 10(1). PMID: 32968172    Free PMC article.
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.
Marco Maria Aiello, Cinzia Solinas, +8 authors, Hector Josè Soto Parra.
Front Oncol, 2020 Sep 29; 10. PMID: 32983959    Free PMC article.
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Katia Khoury, Antoinette R Tan, +10 authors, Filipa Lynce.
Front Oncol, 2020 Sep 29; 10. PMID: 32983983    Free PMC article.
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.
Valsamo Anagnostou, Noushin Niknafs, +32 authors, Victor E Velculescu.
Nat Cancer, 2020 Sep 29; 1(1). PMID: 32984843    Free PMC article.
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Fabio Gomes, Melisa Wong, +4 authors, Andrea Luciani.
Br J Cancer, 2020 Jul 23; 123(6). PMID: 32694695    Free PMC article.
Hyperprogression: A novel response pattern under immunotherapy.
Xue-Jiao Han, Aqu Alu, +2 authors, Xia-Wei Wei.
Clin Transl Med, 2020 Oct 01; 10(5). PMID: 32997401    Free PMC article.
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Mohamed E Salem, J Nicholas Bodor, +10 authors, Michael J Hall.
Int J Cancer, 2020 May 26; 147(10). PMID: 32449172    Free PMC article.
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Danilo Rocco, Luigi D Gravara, Cesare Gridelli.
Curr Clin Pharmacol, 2019 Aug 11; 15(1). PMID: 31400270    Free PMC article.
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Huabin Hu, Longjiang She, +7 authors, Jin Huang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014826    Free PMC article.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Mariona Riudavets, Joaquin Mosquera, +9 authors, Margarita Majem.
Front Oncol, 2020 Oct 06; 10. PMID: 33014837    Free PMC article.
Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?.
Pu Xiaoyu, Ge Chao, Dong Lihua, Chang Pengyu.
Gut Microbes, 2020 Mar 29; 11(4). PMID: 32216675    Free PMC article.
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kyoichi Kaira, Atsuto Mouri, +3 authors, Kunihiko Kobayashi.
BMC Cancer, 2020 Oct 08; 20(1). PMID: 33023530    Free PMC article.
The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome.
Christian Brueffer, Sergii Gladchuk, +12 authors, Lao H Saal.
EMBO Mol Med, 2020 Sep 15; 12(10). PMID: 32926574    Free PMC article.
Cancer patients in SARS-CoV-2 infection: a single-center experience from Wuhan.
Jiafeng Wang, Jun Zhang, +6 authors, Minghua Ge.
J Cancer, 2020 Oct 10; 11(21). PMID: 33033507    Free PMC article.
Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial.
Chao Ren, Zong-Jiong Mai, +7 authors, Rui-Hua Xu.
Am J Cancer Res, 2020 Oct 13; 10(9). PMID: 33042628    Free PMC article.
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation.
Shicong Zhu, Yang Fu, +2 authors, Jun Wang.
Front Oncol, 2020 Oct 13; 10. PMID: 33042827    Free PMC article.
Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma.
Xiaoling Xu, Lei Cheng, Yun Fan, Weimin Mao.
Front Oncol, 2020 Oct 13; 10. PMID: 33042835    Free PMC article.
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Zhijie Wang, Jianming Ying, +13 authors, Jie Wang.
JAMA Netw Open, 2020 Oct 06; 3(10). PMID: 33017026    Free PMC article.
Immune checkpoint inhibitor-related dermatologic adverse events.
Amaris N Geisler, Gregory S Phillips, +5 authors, Mario E Lacouture.
J Am Acad Dermatol, 2020 May 27; 83(5). PMID: 32454097    Free PMC article.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Barzin Y Nabet, Mohammad S Esfahani, +29 authors, Maximilian Diehn.
Cell, 2020 Oct 03; 183(2). PMID: 33007267    Free PMC article.
Genetic Features of Lung Adenocarcinoma with Ground- Glass Opacity: What Causes the Invasiveness of Lung Adenocarcinoma?
Dohun Kim, Jong-Young Lee, Jin Young Yoo, Jun Yeun Cho.
Korean J Thorac Cardiovasc Surg, 2020 Oct 07; 53(5). PMID: 33020345    Free PMC article.
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Xin Yan, Xuan Tian, Zhiqiang Wu, Weidong Han.
Front Oncol, 2020 Oct 20; 10. PMID: 33072551    Free PMC article.
Systematic Review.
A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma.
Luochengling Xiang, Xiao Fu, +4 authors, Tao Tian.
Front Oncol, 2020 Oct 20; 10. PMID: 33072585    Free PMC article.
DNA Repair and Signaling in Immune-Related Cancer Therapy.
Sangeeta Kakoti, Hiro Sato, +2 authors, Atsushi Shibata.
Front Mol Biosci, 2020 Oct 27; 7. PMID: 33102516    Free PMC article.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Wen-Jia Shi, Wei Zhao.
Chin Med J (Engl), 2020 Sep 23; 133(20). PMID: 32960841    Free PMC article.
Lung cancer treatment in the era of immunotherapy.
Yang Xu, Liang-An Chen.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969863    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Dongmei Xu, Hongmei Liu, +7 authors, Yuan Tian.
Medicine (Baltimore), 2020 Oct 09; 99(41). PMID: 33031304    Free PMC article.
Systematic Review.
Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Hui-Ching Wang, Tsung-Jang Yeh, +2 authors, Shih-Feng Cho.
Int J Mol Sci, 2020 Oct 21; 21(20). PMID: 33076306    Free PMC article.
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Zhangfeng Huang, Wenhao Su, +6 authors, Wenjie Jiao.
Front Pharmacol, 2020 Oct 30; 11. PMID: 33117170    Free PMC article.
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Maitane Ocáriz-Díez, Mara Cruellas, +10 authors, Eva M Gálvez.
Front Oncol, 2020 Oct 30; 10. PMID: 33117698    Free PMC article.
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].
Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer.
Zhongguo Fei Ai Za Zhi, 2020 Sep 22; 23(9). PMID: 32957170    Free PMC article.
From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy.
Andrea Sesma, Julián Pardo, +12 authors, Rodrigo Lastra.
Cancers (Basel), 2020 Oct 18; 12(10). PMID: 33066479    Free PMC article.
Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.
Ning Yang, Pin-Liang Zhang, Zeng-Jun Liu.
Medicine (Baltimore), 2020 Nov 01; 99(44). PMID: 33126358    Free PMC article.
Biomarkers in immunotherapy: literature review and future directions.
Rebecca Pharaon, Maria A Koczywas, +2 authors, Erminia Massarelli.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145089    Free PMC article.
Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.
Lujun Chen, Runzi Sun, +9 authors, Binfeng Lu.
Cancer Immunol Res, 2020 Sep 13; 8(11). PMID: 32917659    Free PMC article.
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Changxia Shao, Gerald Li, +10 authors, Wei Zhou.
JAMA Netw Open, 2020 Oct 30; 3(10). PMID: 33119110    Free PMC article.
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Karsten A Pilones, Michal Hensler, +5 authors, Silvia C Formenti.
Oncoimmunology, 2020 Nov 06; 9(1). PMID: 33150045    Free PMC article.
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
Kyle K Payne, Jessica A Mine, +24 authors, Jose R Conejo-Garcia.
Science, 2020 Aug 21; 369(6506). PMID: 32820120    Free PMC article.
De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.
Samuel T Workenhe, Andrew Nguyen, +12 authors, Karen L Mossman.
Commun Biol, 2020 Nov 06; 3(1). PMID: 33149194    Free PMC article.
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Pierre-Olivier Gaudreau, J Jack Lee, John V Heymach, Don L Gibbons.
Clin Lung Cancer, 2020 Apr 18; 21(4). PMID: 32299768    Free PMC article.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, +16 authors, Wolfgang Janni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173239    Free PMC article.
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
K Bishay, P Tandon, +2 authors, J D McCurdy.
Curr Oncol, 2020 Nov 12; 27(5). PMID: 33173388    Free PMC article.
Systematic Review.
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Shumin Li, Chengyan Zhang, Guanchao Pang, Pingli Wang.
Front Immunol, 2020 Nov 13; 11. PMID: 33178229    Free PMC article.
Systematic Review.
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
Priya Veluswamy, Max Wacker, Maximilian Scherner, Jens Wippermann.
Int J Mol Sci, 2020 Nov 05; 21(21). PMID: 33142805    Free PMC article.
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials.
Carmen Criscitiello, Antonio Marra, +4 authors, Giuseppe Curigliano.
Oncologist, 2020 Aug 14; 25(11). PMID: 32785940    Free PMC article.
Early palliative care of non-small cell lung cancer in the context of immunotherapy.
Małgorzata Pieniążek, Piotr Pawlak, Barbara Radecka.
Oncol Lett, 2020 Nov 17; 20(6). PMID: 33193856    Free PMC article.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival.
Yanmei Gao, Chunhe Yang, +3 authors, Yadong Yang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194669    Free PMC article.
Genomic alterations of whole exome sequencing in esophageal squamous cell carcinoma before and after radiotherapy.
Guixiang Weng, Wei Zhao, +6 authors, Shuanghu Yuan.
J Thorac Dis, 2020 Nov 20; 12(10). PMID: 33209427    Free PMC article.
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Bin Wu, Shun Lu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209600    Free PMC article.
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
Pamela Abdayem, David Planchard.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209637    Free PMC article.
Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.
Jun Gong, Sandip Patel, +9 authors, Andrew E Hendifar.
JCO Precis Oncol, 2020 Nov 21; 4. PMID: 33215052    Free PMC article.
Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
Ilseon Hwang, Jeong Won Kim, +7 authors, Stephen M Hewitt.
J Transl Med, 2020 Nov 25; 18(1). PMID: 33228719    Free PMC article.
Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab.
Kengo Kuriyama, Takehiko Yokobori, +7 authors, Hiroshi Saeki.
Oncol Lett, 2020 Nov 27; 21(1). PMID: 33240417    Free PMC article.
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer.
Elisa Gobbini, Aurélie Swalduz, +5 authors, Pierre Saintigny.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114393    Free PMC article.
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.
Sridhar Nimmagadda.
Cancers (Basel), 2020 Nov 04; 12(11). PMID: 33137949    Free PMC article.
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs.
Maureen L Drakes, Cheryl M Czerlanis, Patrick J Stiff.
Cancers (Basel), 2020 Nov 14; 12(11). PMID: 33182298    Free PMC article.
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.
James J Lee, Edward Chu.
Clin Colorectal Cancer, 2018 Aug 04; 17(4). PMID: 30072278    Free PMC article.
[Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma].
S Ormanns.
Pathologe, 2018 Oct 27; 39(Suppl 2). PMID: 30361776
The lung microenvironment: an important regulator of tumour growth and metastasis.
Nasser K Altorki, Geoffrey J Markowitz, +5 authors, Vivek Mittal.
Nat Rev Cancer, 2018 Dec 12; 19(1). PMID: 30532012    Free PMC article.
Highly Cited. Review.
LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
Ling Cai, ShinYi Lin, +15 authors, Yang Xie.
Oncogene, 2018 Dec 12; 38(14). PMID: 30532070    Free PMC article.
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Florian Wirsdörfer, Simone de Leve, Verena Jendrossek.
Int J Mol Sci, 2018 Dec 24; 20(1). PMID: 30577587    Free PMC article.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Sung Won Lim, Myung-Ju Ahn.
Korean J Intern Med, 2019 Jan 08; 34(1). PMID: 30612418    Free PMC article.
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.
Anna M Krichevsky, Erik J Uhlmann.
Neurotherapeutics, 2019 Jan 16; 16(2). PMID: 30644073    Free PMC article.
Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
Zhen Xiang, Yingyan Yu.
Front Med, 2019 Jan 20; 13(1). PMID: 30659409
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
Min Zhang, Jingwen Yang, +3 authors, Qijun Qian.
Front Med, 2019 Jan 27; 13(1). PMID: 30680606
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.
Manolo D'Arcangelo, Armida D'Incecco, +14 authors, Federico Cappuzzo.
Oncotarget, 2019 Feb 08; 10(5). PMID: 30728907    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan.
Nat Rev Cancer, 2019 Feb 14; 19(3). PMID: 30755690    Free PMC article.
Highly Cited. Review.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
J Corral, M Majem, +7 authors, M P López Criado.
Clin Transl Oncol, 2019 Feb 17; 21(9). PMID: 30771085
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
Implementing TMB measurement in clinical practice: considerations on assay requirements.
Reinhard Büttner, John W Longshore, +4 authors, Frédérique Penault-Llorca.
ESMO Open, 2019 Feb 23; 4(1). PMID: 30792906    Free PMC article.
Highly Cited.
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Yuichi Ozawa, Yusuke Amano, +8 authors, Takafumi Suda.
Med Oncol, 2019 Mar 03; 36(4). PMID: 30825015
Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.
Satoru Senoo, Kiichiro Ninomiya, Katsuyuki Hotta, Katsuyuki Kiura.
Int J Clin Oncol, 2019 Mar 09; 24(5). PMID: 30847617
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
Helen Adderley, Fiona H Blackhall, Colin R Lindsay.
EBioMedicine, 2019 Mar 11; 41. PMID: 30852159    Free PMC article.
Highly Cited. Review.
Prognostic impact of mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia.
Anudishi Tyagi, Raja Pramanik, +2 authors, Sameer Bakhshi.
Oncotarget, 2019 Mar 14; 10(13). PMID: 30863493    Free PMC article.
<Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Vitaly Kochin, Hiroyoshi Nishikawa.
Nagoya J Med Sci, 2019 Apr 10; 81(1). PMID: 30962651    Free PMC article.
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Fabinshy Thangarajah, Bernd Morgenstern, +9 authors, Anne Maria Schultheis.
J Cancer Res Clin Oncol, 2019 Apr 12; 145(6). PMID: 30972492
Telomerase-Targeted Cancer Immunotherapy.
Eishiro Mizukoshi, Shuichi Kaneko.
Int J Mol Sci, 2019 Apr 25; 20(8). PMID: 31013796    Free PMC article.
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Yanhui Chen, Quanxing Liu, +8 authors, Henghui Zhang.
J Exp Clin Cancer Res, 2019 May 16; 38(1). PMID: 31088500    Free PMC article.
Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Wenwei Yang, Shuquan Li, Qingrui Yang.
Medicine (Baltimore), 2019 May 18; 98(20). PMID: 31096532    Free PMC article.
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
Hsiang-Ling Ho, Teh-Ying Chou, +4 authors, Hao-Wei Teng.
J Cancer Res Clin Oncol, 2019 May 28; 145(7). PMID: 31129768
Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
Sung Yong Lee, Jee Youn Oh, +5 authors, Chien-Fu Hung.
J Biomed Sci, 2019 May 28; 26(1). PMID: 31133013    Free PMC article.
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Lihu Gu, Parikshit Asutosh Khadaroo, +8 authors, Manman Chen.
BMC Cancer, 2019 Jun 12; 19(1). PMID: 31182049    Free PMC article.
Systematic Review.
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Anand Rotte.
J Exp Clin Cancer Res, 2019 Jun 15; 38(1). PMID: 31196207    Free PMC article.
Highly Cited. Review.
Advances in cancer immunotherapy 2019 - latest trends.
Stephan Kruger, Matthias Ilmer, +12 authors, Michael von Bergwelt-Baildon.
J Exp Clin Cancer Res, 2019 Jun 21; 38(1). PMID: 31217020    Free PMC article.
Highly Cited. Review.
New emerging targets in cancer immunotherapy: the role of TIM3.
Alex Friedlaender, Alfredo Addeo, Giuseppe Banna.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275616    Free PMC article.
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
Matteo Lambertini, Matthias Preusser, Christoph C Zielinski.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275617    Free PMC article.
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Anna S Berghoff, Beatriz Bellosillo, +8 authors, Christoph C Zielinski.
ESMO Open, 2019 Jul 13; 4(3). PMID: 31297240    Free PMC article.
The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis.
Heli Shang, Zewen Zhang, +7 authors, Yuan Tian.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348245    Free PMC article.
Systematic Review.
Brain metastases from esophageal cancer: A retrospective analysis of the outcome after surgical resection followed by radiotherapy.
Pantelis Stavrinou, Lars Plambeck, +3 authors, Stefan Grau.
Medicine (Baltimore), 2019 Aug 24; 98(34). PMID: 31441840    Free PMC article.
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Mehmet Asim Bilen, Julie M Shabto, +17 authors, R Donald Harvey.
BMC Cancer, 2019 Aug 30; 19(1). PMID: 31464611    Free PMC article.
Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis.
Yao Ma, Xiao-Fei Feng, Wan-Xia Yang, Chong-Ge You.
Biomed Res Int, 2019 Sep 20; 2019. PMID: 31534952    Free PMC article.
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Khalil Choucair, Susan Morand, +3 authors, John Nemunaitis.
Cancer Gene Ther, 2020 Apr 29; 27(12). PMID: 32341410
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Jiabu Ye, Xiang Ji, +2 authors, Pralay Mukhopadhyay.
Clin Pharmacol Ther, 2020 Jun 22; 108(6). PMID: 32564368    Free PMC article.
Systematic Review.
Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Hiroyuki Minemura, Hiroshi Moriya, +12 authors, Yoko Shibata.
Thorac Cancer, 2020 Oct 13; 11(12). PMID: 33044045    Free PMC article.
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Dan Sha, Zhaohui Jin, +3 authors, Frank A Sinicrope.
Cancer Discov, 2020 Nov 04; 10(12). PMID: 33139244    Free PMC article.
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients.
Ilaria Grazia Zizzari, Alessandra Di Filippo, +12 authors, Chiara Napoletano.
J Pers Med, 2020 Nov 08; 10(4). PMID: 33158018    Free PMC article.
The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
Mahdi Golkaram, Chen Zhao, +2 authors, Sven Bilke.
PLoS Comput Biol, 2020 Nov 10; 16(11). PMID: 33166276    Free PMC article.
Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy.
Silvia M Bacot, Taylor A Harper, +6 authors, Gerald M Feldman.
Int J Mol Sci, 2020 Dec 03; 21(23). PMID: 33261003    Free PMC article.
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Siwen Hu-Lieskovan, Srabani Bhaumik, +14 authors, Holden T Maecker.
J Immunother Cancer, 2020 Dec 04; 8(2). PMID: 33268350    Free PMC article.
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Wolfgang M Brueckl, Joachim H Ficker, Gloria Zeitler.
BMC Cancer, 2020 Dec 05; 20(1). PMID: 33272262    Free PMC article.
Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Jiaqiong Lin, Yan Lin, Zena Huang, Xiaoyong Li.
Comput Math Methods Med, 2020 Dec 05; 2020. PMID: 33273963    Free PMC article.
Changing paradigm in advanced and metastatic non-small cell lung cancer.
Dipesh Uprety, Kaushal Parikh, +2 authors, Konstantinos Leventakos.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282404    Free PMC article.
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Yang Liu, Jing Cai, +10 authors, Jiankai Liang.
Cell Death Dis, 2020 Dec 15; 11(12). PMID: 33311488    Free PMC article.
Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
Mitchell S von Itzstein, Amrit S Gonugunta, +2 authors, David E Gerber.
Cancer J, 2020 Dec 11; 26(6). PMID: 33298724    Free PMC article.
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.
Zsofia D Drobni, Raza M Alvi, +17 authors, Tomas G Neilan.
Circulation, 2020 Oct 03; 142(24). PMID: 33003973    Free PMC article.
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Priyanka Patel, Doraid Alrifai, +2 authors, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293672    Free PMC article.
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients.
Amin Haghighat Jahromi, Donald A Barkauskas, +5 authors, Razelle Kurzrock.
EJNMMI Res, 2020 Dec 10; 10(1). PMID: 33296034    Free PMC article.
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Kamila Wojas-Krawczyk, Tomasz Kubiatowski.
Front Oncol, 2020 Dec 18; 10. PMID: 33330041    Free PMC article.
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Yutian Zou, Xiaoqian Hu, +5 authors, Xiaoming Xie.
EBioMedicine, 2020 Dec 15; 63. PMID: 33310681    Free PMC article.
Systematic Review.
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors.
Marcin Nicoś, Paweł Krawczyk, Nicola Crosetto, Janusz Milanowski.
Front Oncol, 2020 Dec 22; 10. PMID: 33344229    Free PMC article.
Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Yuxin Sun, Chi Shao, +6 authors, Zuojun Xu.
Asia Pac J Clin Oncol, 2020 Aug 07; 16(6). PMID: 32757454    Free PMC article.
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Veronica Ghini, Letizia Laera, +6 authors, Daniele Pozzessere.
Cancers (Basel), 2020 Dec 04; 12(12). PMID: 33265926    Free PMC article.
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Boris Duchemann, Jordi Remon, +10 authors, Nathalie Chaput.
Cancers (Basel), 2020 Dec 09; 12(12). PMID: 33287347    Free PMC article.
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Laura Boyero, Amparo Sánchez-Gastaldo, +3 authors, Reyes Bernabé-Caro.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322522    Free PMC article.
The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection.
Gabriela Marsavela, Peter A Johansson, +12 authors, Leslie Calapre.
Cancers (Basel), 2020 Dec 20; 12(12). PMID: 33339135    Free PMC article.
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Nityam Rathi, Taylor Ryan McFarland, +2 authors, Umang Swami.
Drugs, 2020 Dec 29; 81(2). PMID: 33369720    Free PMC article.
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Alexey Berezhnoy, Bradley J Sumrow, +16 authors, Paul A Moore.
Cell Rep Med, 2020 Dec 31; 1(9). PMID: 33377134    Free PMC article.
Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.
James Newman, Nagashree Seetharamu, Muhammad Wasif Saif.
Cancer Med J, 2020 Dec 31; 3(Suppl 2). PMID: 33377136    Free PMC article.
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
Benjamin Ruf, Bernd Heinrich, Tim F Greten.
Cell Mol Immunol, 2020 Nov 26; 18(1). PMID: 33235387    Free PMC article.
Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
Qian Jiang, Mei Feng, +3 authors, Ting Yu.
Front Pharmacol, 2021 Jan 05; 11. PMID: 33390946    Free PMC article.
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma.
Longrong Wang, Kai Yan, +6 authors, Lu Wang.
J Cancer, 2021 Jan 05; 12(1). PMID: 33391418    Free PMC article.
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Tao Jiang, Liyan Jiang, +41 authors, Caicun Zhou.
Theranostics, 2021 Jan 05; 11(1). PMID: 33391473    Free PMC article.
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Michael Zhang, Adrian J Rodrigues, +11 authors, Gordon Li.
J Neurooncol, 2021 Jan 09; 152(1). PMID: 33415659    Free PMC article.
Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report.
Xiao Tang, Shiqing Chen, +7 authors, Yue He.
Ann Transl Med, 2020 May 02; 8(6). PMID: 32355846    Free PMC article.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Kazuko Sakai, Masahiro Tsuboi, +25 authors, Kazuto Nishio.
Cancer Sci, 2020 Nov 14; 112(1). PMID: 33185928    Free PMC article.
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Seo Ree Kim, Sang Hoon Chun, +10 authors, Jin Hyoung Kang.
BMC Cancer, 2021 Jan 07; 21(1). PMID: 33402127    Free PMC article.
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Daan P Hurkmans, Els M E Verdegaal, +18 authors, Sjoerd H van der Burg.
J Immunother Cancer, 2021 Jan 12; 8(2). PMID: 33427690    Free PMC article.
Targeting metastatic cancer.
Karuna Ganesh, Joan Massagué.
Nat Med, 2021 Jan 15; 27(1). PMID: 33442008    Free PMC article.
[Research Progress in the Treatment of Brain Metastases 
from Non-small Cell Lung Cancer].
Xue Han, Hongmei Li.
Zhongguo Fei Ai Za Zhi, 2020 Dec 29; 23(12). PMID: 33357316    Free PMC article.
Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
Sławomir Poletajew, Wojciech Krajewski, Piotr Kryst.
Transl Androl Urol, 2021 Jan 19; 9(6). PMID: 33457220    Free PMC article.
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer.
Yuehong Cui, Qian Li, +9 authors, Tianshu Liu.
Front Oncol, 2021 Jan 23; 10. PMID: 33479597    Free PMC article.
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
Norikazu Matsuo, Koichi Azuma, +4 authors, Tomoaki Hoshino.
Invest New Drugs, 2021 Jan 24; 39(4). PMID: 33483882
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Hironori Uruga, Mari Mino-Kenudson.
Virchows Arch, 2021 Jan 25; 478(1). PMID: 33486574
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Zi Yin, Min Yu, +5 authors, Sheng Chen.
J Immunother Cancer, 2021 Jan 22; 9(1). PMID: 33472857    Free PMC article.
Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?
Ramon Andrade De Mello, Jin-Hui Zhu, +8 authors, Georgio Antoniou.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489794    Free PMC article.
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Yanjun Xu, Hui Li, +5 authors, Yun Fan.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489799    Free PMC article.
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
Wenhua Liang, Kaican Cai, +42 authors, Jianxing He.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489828    Free PMC article.
Alterations of DNA damage repair in cancer: from mechanisms to applications.
Minlin Jiang, Keyi Jia, +7 authors, Caicun Zhou.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490197    Free PMC article.
miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma.
Yu Xia, Qi Wang, +4 authors, Xiaofeng Duan.
Biomed Res Int, 2021 Jan 26; 2020. PMID: 33490233    Free PMC article.
Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.
Bo Ling, Guangbin Ye, +3 authors, Qianli Tang.
Front Mol Biosci, 2021 Jan 29; 7. PMID: 33505988    Free PMC article.
Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.
Liliang Xia, Hui Wang, +12 authors, Ying Wang.
Sci China Life Sci, 2021 Feb 02; 64(10). PMID: 33521853
DNA-protein biomarkers for immunotherapy in the era of precision oncology.
Binnari Kim, So Young Kang, Kyoung-Mee Kim.
J Pathol Transl Med, 2020 Nov 07; 55(1). PMID: 33153244    Free PMC article.
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Jia Wang, Xiaolu Zhang, +5 authors, Changgang Sun.
Aging (Albany NY), 2020 Nov 26; 13(1). PMID: 33234738    Free PMC article.
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Zhiming Chen, Ji Chen, +5 authors, Haitao Ma.
Aging (Albany NY), 2020 Dec 09; 13(1). PMID: 33288738    Free PMC article.
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study.
Yaolin Chen, Xiangzhen Liu, +4 authors, Pengfei Chen.
BMC Cancer, 2021 Feb 04; 21(1). PMID: 33530966    Free PMC article.
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Xiaozheng Chen, Aiqin Gao, +9 authors, Yuping Sun.
Theranostics, 2021 Feb 05; 11(7). PMID: 33537094    Free PMC article.
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Eric Nadler, Bhakti Arondekar, +4 authors, Vivek Pawar.
J Cancer Res Clin Oncol, 2020 Dec 03; 147(3). PMID: 33263865    Free PMC article.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, +11 authors, Israel Lung Cancer Group.
Oncoimmunology, 2021 Feb 09; 10(1). PMID: 33552685    Free PMC article.
Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
Lianghao Zhang, Longqing Li, +3 authors, Xuepei Zhang.
Front Oncol, 2021 Feb 09; 10. PMID: 33552945    Free PMC article.
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Yanbin Zhao, Minghui Zhang, +3 authors, Yan Wang.
Front Oncol, 2021 Feb 09; 10. PMID: 33552963    Free PMC article.
Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Da-Li Chen, Qing-Yuan Li, Qun-You Tan.
J Thorac Dis, 2021 Feb 12; 13(1). PMID: 33569202    Free PMC article.
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
Caroline Huynh, Logan A Walsh, Jonathan D Spicer.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569337    Free PMC article.
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock.
Cancer Cell, 2020 Oct 31; 39(2). PMID: 33125859    Free PMC article.
Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574895    Free PMC article.
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.
Congkuan Song, Zhiquan Wu, +4 authors, Weidong Hu.
Front Cell Dev Biol, 2021 Feb 16; 9. PMID: 33585490    Free PMC article.
Laminin γ2-mediating T cell exclusion attenuates response to anti-PD-1 therapy.
Lei Li, Jia-Ru Wei, +11 authors, Xin-Yuan Guan.
Sci Adv, 2021 Feb 05; 7(6). PMID: 33536206    Free PMC article.
Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Hitomi Kawaji, Makoto Kubo, +16 authors, Masafumi Nakamura.
Cancer Med, 2020 Dec 05; 10(2). PMID: 33274848    Free PMC article.
Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Chengde Wu, Xiang Rao, Wei Lin.
Cancer Med, 2020 Dec 15; 10(3). PMID: 33314730    Free PMC article.
Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning.
Yachao Yang, Jialiang Yang, +4 authors, Kaimei Huang.
Front Genet, 2021 Feb 27; 12. PMID: 33633793    Free PMC article.
MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer.
Jiahao Huang, Haizhou Liu, +5 authors, Weizhong Tang.
Front Oncol, 2021 Feb 27; 10. PMID: 33634010    Free PMC article.
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.
Florian Huemer, Michael Leisch, +2 authors, Richard Greil.
Pharmaceuticals (Basel), 2021 Feb 04; 14(2). PMID: 33530393    Free PMC article.
Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC).
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis.
Cancers (Basel), 2021 Feb 10; 13(4). PMID: 33557047    Free PMC article.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability.
Dongdong Yang, Jinling Yu, +3 authors, Jing Hu.
Front Cell Dev Biol, 2021 Mar 02; 9. PMID: 33644056    Free PMC article.
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.
Mengke Niu, Ming Yi, +2 authors, Kongming Wu.
Exp Hematol Oncol, 2021 Mar 04; 10(1). PMID: 33653420    Free PMC article.
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.
M A Amrein, E D Bührer, +8 authors, A F Ochsenbein.
Cancer Immunol Immunother, 2020 Aug 09; 70(2). PMID: 32767058    Free PMC article.
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.
L Leon-Mateos, M J Garcia-Velloso, +6 authors, L Gorospe.
Clin Transl Oncol, 2020 Jul 06; 23(3). PMID: 32623581    Free PMC article.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma.
Yong Cheng, Yanxiang Zhang, +7 authors, Xiaoqun Ye.
Front Genet, 2021 Mar 09; 11. PMID: 33679868    Free PMC article.
Personalized Immuno-Oncology.
Kewal K Jain.
Med Princ Pract, 2020 Aug 26; 30(1). PMID: 32841942    Free PMC article.
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Hongbin Zhang, Yuan Wang, +11 authors, Min Zhao.
Oncol Lett, 2021 Mar 12; 21(4). PMID: 33692861    Free PMC article.
Recent advances in preclinical models for lung squamous cell carcinoma.
Yuanwang Pan, Han Han, +2 authors, Kwok-Kin Wong.
Oncogene, 2021 Mar 13; 40(16). PMID: 33707749
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
Manuel Caitano Maia, Meghan Salgia, Sumanta K Pal.
Nat Rev Urol, 2020 Mar 24; 17(5). PMID: 32203306
Mutational signatures in squamous cell carcinoma of the lung.
Atsushi Osoegawa, Kazuki Takada, +8 authors, Masaki Mori.
J Thorac Dis, 2021 Mar 16; 13(2). PMID: 33717580    Free PMC article.
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Chuling Li, Meiqi Shi, +9 authors, Yong Song.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718021    Free PMC article.
Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure.
Kyoichi Kaira, Kunihiko Kobayashi, +7 authors, Hiroshi Kagamu.
Thorac Cancer, 2021 Feb 02; 12(6). PMID: 33522139    Free PMC article.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Alessio Cortellini, Andrea De Giglio, +48 authors, Giampiero Porzio.
Thorac Cancer, 2021 Feb 03; 12(6). PMID: 33527756    Free PMC article.
Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, Ladan Langroudi.
Transl Oncol, 2021 Mar 09; 14(5). PMID: 33684837    Free PMC article.
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Haoyang Li, Jinghui Wang.
Zhongguo Fei Ai Za Zhi, 2021 Jan 29; 24(2). PMID: 33508897    Free PMC article.
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Landon C Brown, Matthew D Tucker, +14 authors, Andrew J Armstrong.
J Immunother Cancer, 2021 Mar 04; 9(3). PMID: 33653800    Free PMC article.
Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Shuhang Wang, Yuan Fang, +6 authors, Ning Li.
Front Immunol, 2021 Mar 19; 12. PMID: 33732253    Free PMC article.
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Zhaozhen Wu, Pengfei Cui, +10 authors, Yi Hu.
Clin Med Insights Oncol, 2021 Mar 20; 15. PMID: 33737855    Free PMC article.
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
Vanesa Gutiérrez Calderón, Alexandra Cantero González, +2 authors, Antonio Rueda Domínguez.
Ther Adv Med Oncol, 2021 Mar 23; 13. PMID: 33747147    Free PMC article.
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Yunfei Shi, Youming Lei, +8 authors, Qing Zhou.
Cancer Med, 2021 Mar 04; 10(7). PMID: 33655698    Free PMC article.
Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Alexandra M Haugh, April K S Salama, Douglas B Johnson.
Hematol Oncol Clin North Am, 2021 Mar 25; 35(1). PMID: 33759769    Free PMC article.
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Jun Shao, Chengdi Wang, +3 authors, Weimin Li.
Biosci Rep, 2020 Apr 22; 40(5). PMID: 32315071    Free PMC article.
Systematic Review.
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.
Amirali Karimi, Sanam Alilou, Hamid Reza Mirzaei.
Front Oncol, 2021 Mar 27; 11. PMID: 33767992    Free PMC article.
Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Incheol Seo, Hye Won Lee, +6 authors, Sung Uk Bae.
J Immunother Cancer, 2021 Mar 12; 9(3). PMID: 33692216    Free PMC article.
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Vineel Bhatlapenumarthi, Anannya Patwari, Antoine J Harb.
J Cancer Res Clin Oncol, 2021 Mar 29; 147(9). PMID: 33774736
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Minghao Wu, Yanyan Zhang, +3 authors, Zhaoxiang Ye.
Radiol Imaging Cancer, 2019 Nov 29; 1(2). PMID: 33778682    Free PMC article.
A view on drug resistance in cancer.
Neil Vasan, José Baselga, David M Hyman.
Nature, 2019 Nov 15; 575(7782). PMID: 31723286    Free PMC article.
Highly Cited. Review.
The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Ryuma Tokunaga, Joanne Xiu, +17 authors, Heinz-Josef Lenz.
Eur J Cancer, 2020 Oct 21; 140. PMID: 33080474    Free PMC article.
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
Nicholas Giustini, Lyudmila Bazhenova.
Lung Cancer (Auckl), 2021 Apr 02; 12. PMID: 33790679    Free PMC article.
The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Zhang Nan, Wang Guoqing, +4 authors, Wang Rong.
Biomed Res Int, 2021 Apr 02; 2021. PMID: 33791360    Free PMC article.
Systematic Review.
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy.
Sabina Sangaletti, Roberto Ferrara, +2 authors, Mario Paolo Colombo.
Cancer Immunol Immunother, 2021 Apr 03; 70(9). PMID: 33797567    Free PMC article.
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Eugene Shenderov, Karim Boudadi, +14 authors, Emmanuel S Antonarakis.
Prostate, 2021 Feb 27; 81(6). PMID: 33636027    Free PMC article.
Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer.
Ying Liu, Minghao Wu, +15 authors, Zhaoxiang Ye.
Front Oncol, 2021 Apr 06; 11. PMID: 33816314    Free PMC article.
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Maximilian Boesch, Florent Baty, +4 authors, Martin H Brutsche.
Br J Cancer, 2021 Apr 08; 125(3). PMID: 33824481    Free PMC article.
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Valérie Gounant, Michael Duruisseaux, +14 authors, Gérard Zalcman.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33801285    Free PMC article.
The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Hong Yuan, Jing Liu, Jun Zhang.
Molecules, 2021 Apr 04; 26(5). PMID: 33807509    Free PMC article.
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Masayuki Takeda, Takayuki Takahama, +21 authors, Kazuto Nishio.
Oncologist, 2020 Dec 17; 26(4). PMID: 33325566    Free PMC article.
Gene expression and immune infiltration in melanoma patients with different mutation burden.
Liwei Wang, Fu Chen, +3 authors, Zhengjian Yan.
BMC Cancer, 2021 Apr 11; 21(1). PMID: 33836680    Free PMC article.
Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.
Clifford M Csizmar, Stephen M Ansell.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33804869    Free PMC article.
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Margarita Majem, Manuel Cobo, +9 authors, Luis Paz-Ares.
J Clin Med, 2021 Apr 04; 10(7). PMID: 33810441    Free PMC article.
Panels and models for accurate prediction of tumor mutation burden in tumor samples.
Elizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje.
NPJ Precis Oncol, 2021 Apr 15; 5(1). PMID: 33850256    Free PMC article.
COL1A1 is a prognostic biomarker and correlated with immune infiltrates in lung cancer.
Qishun Geng, Zhibo Shen, Lifeng Li, Jie Zhao.
PeerJ, 2021 Apr 15; 9. PMID: 33850663    Free PMC article.
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Neal Ready, Anna F Farago, +12 authors, Scott J Antonia.
J Thorac Oncol, 2018 Oct 14; 14(2). PMID: 30316010    Free PMC article.
Highly Cited.
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Elena María Brozos-Vázquez, Roberto Díaz-Peña, +4 authors, Rafael López-López.
Cancer Immunol Immunother, 2020 Oct 29; 70(5). PMID: 33113004
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.
R Kleef, R Nagy, +7 authors, T Bakacs.
Cancer Immunol Immunother, 2020 Nov 06; 70(5). PMID: 33151369    Free PMC article.
A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.
Chan Xie, Hewei Wu, +6 authors, Liang Peng.
Aging (Albany NY), 2021 Mar 14; 13(6). PMID: 33714200    Free PMC article.
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Biagio Ricciuti, Greg Jones, +8 authors, Mark Awad.
J Immunother Cancer, 2021 Mar 28; 9(3). PMID: 33771889    Free PMC article.
Identification of important genes and drug repurposing based on clinical-centered analysis across human cancers.
Ying Li, Ya-Ping Dong, +4 authors, Hong-Yang Wang.
Acta Pharmacol Sin, 2020 Jun 20; 42(2). PMID: 32555508    Free PMC article.
Effect of prior therapy on tumor mutational burden in NSCLC.
Sushma Jonna, Ari Vanderwalde, +5 authors, Stephen V Liu.
Transl Lung Cancer Res, 2021 Apr 24; 10(3). PMID: 33889505    Free PMC article.
Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients.
Gang Guo, Gaofeng Li, +6 authors, Yunfei Shi.
Front Oncol, 2021 Apr 24; 11. PMID: 33889543    Free PMC article.
Is immunotherapy in the future of therapeutic management of sarcomas?
Ottavia Clemente, Alessandro Ottaiano, +9 authors, Salvatore Tafuto.
J Transl Med, 2021 Apr 28; 19(1). PMID: 33902630    Free PMC article.
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.
Ji-Yeon Kim, Hae Hyun Jung, +9 authors, Young-Hyuck Im.
Breast Cancer Res Treat, 2020 Aug 20; 184(2). PMID: 32812178
The Clinical Implications of Tumor Mutational Burden in Osteosarcoma.
Lu Xie, Yufei Yang, +9 authors, Xiaodong Tang.
Front Oncol, 2021 Apr 27; 10. PMID: 33898301    Free PMC article.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Taofeek K Owonikoko, Keunchil Park, +22 authors, Hye Ryun Kim.
J Clin Oncol, 2021 Mar 09; 39(12). PMID: 33683919    Free PMC article.
A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients.
Xiao Wu, Hongxu Sheng, +5 authors, Jian Hu.
Aging (Albany NY), 2021 Apr 03; 13(7). PMID: 33795529    Free PMC article.
Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.
Daniela Ferreira, Juliana Miranda, +2 authors, Raquel Chaves.
Int J Mol Sci, 2021 May 01; 22(8). PMID: 33916986    Free PMC article.
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Alice Indini, Erika Rijavec, Francesco Grossi.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33918661    Free PMC article.
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, +11 authors, Yi Hu.
Front Oncol, 2021 May 04; 11. PMID: 33937012    Free PMC article.
Systematic Review.
[Predictive diagnostics for checkpoint inhibitors].
Hans-Ulrich Schildhaus, Wilko Weichert.
Pathologe, 2021 May 07; 42(4). PMID: 33956171
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals, Julie R Brahmer, +7 authors, Maria E Suárez-Almazor.
Nat Rev Dis Primers, 2020 May 10; 6(1). PMID: 32382051
Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.
Rituparna Chakrabarti, Bhavya Kapse, Gayatri Mukherjee.
Cancer Rep (Hoboken), 2020 Jul 29; 2(4). PMID: 32721130    Free PMC article.
Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy.
Wen-Xin Luo, Lan Yang, Wei-Min Li.
Chin Med J (Engl), 2021 Jan 08; 134(7). PMID: 33410615    Free PMC article.
Beneficial autoimmunity improves cancer prognosis.
Laurence Zitvogel, Claude Perreault, Olivera J Finn, Guido Kroemer.
Nat Rev Clin Oncol, 2021 May 13; 18(9). PMID: 33976418
Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Shaoqing Liu, Qianjie Tang, +8 authors, Xu He.
Aging (Albany NY), 2021 Apr 07; 13(8). PMID: 33820866    Free PMC article.
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
Chundi Gao, Huayao Li, +6 authors, Changgang Sun.
Front Immunol, 2021 May 11; 12. PMID: 33968045    Free PMC article.
Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis.
Jianyang Fu, Wang-Zhong Li, +4 authors, Changqing Xie.
Front Oncol, 2021 May 11; 11. PMID: 33968750    Free PMC article.
Systematic Review.
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.
Michela Roberto, Andrea Botticelli, +9 authors, Paolo Marchetti.
Front Oncol, 2021 May 11; 11. PMID: 33968762    Free PMC article.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, +4 authors, Virginie Westeel.
Cochrane Database Syst Rev, 2020 Dec 15; 12. PMID: 33316104    Free PMC article.
Systematic Review.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, +4 authors, Virginie Westeel.
Cochrane Database Syst Rev, 2021 May 01; 4. PMID: 33930176    Free PMC article.
Systematic Review.
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
Hao Wang, Shanhao Chen, +16 authors, Caicun Zhou.
Onco Targets Ther, 2021 May 13; 14. PMID: 33976553    Free PMC article.
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.
Katherine E Lindblad, Marina Ruiz de Galarreta, Amaia Lujambio.
Front Immunol, 2021 May 14; 12. PMID: 33981303    Free PMC article.
Identifying Genomic Alterations in Small Cell Lung Cancer Using the Liquid Biopsy of Bronchial Washing Fluid.
Jinfang Zhai, Songyan Han, +15 authors, Weihua Yang.
Front Oncol, 2021 May 15; 11. PMID: 33987084    Free PMC article.
Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
Jun Zhang, Lanfen An, +2 authors, Hongbo Wang.
Ann Transl Med, 2021 May 15; 9(7). PMID: 33987249    Free PMC article.
The Evolution of STING Signaling and Its Involvement in Cancer.
Nimi Vashi, Samuel F Bakhoum.
Trends Biochem Sci, 2021 Jan 20; 46(6). PMID: 33461879    Free PMC article.
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Noura J Choudhury, Adam J Schoenfeld, +9 authors, Gregory J Riely.
Clin Cancer Res, 2021 Mar 10; 27(10). PMID: 33685865    Free PMC article.
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.
A Galvano, V Gristina, +9 authors, V Bazan.
ESMO Open, 2021 May 04; 6(3). PMID: 33940346    Free PMC article.
Systematic Review.
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy.
Changhee Park, Kyeonghun Jeong, +14 authors, Dae Seog Heo.
Cancer Immunol Immunother, 2020 Nov 25; 70(6). PMID: 33230567
From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform?
Haiyi Deng, Chengzhi Zhou.
Transl Lung Cancer Res, 2021 May 21; 10(4). PMID: 34012802    Free PMC article.
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.
Javier Ramos-Paradas, Susana Hernández-Prieto, +17 authors, Luis Paz-Ares.
J Immunother Cancer, 2021 May 09; 9(5). PMID: 33963008    Free PMC article.
Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim.
Front Pharmacol, 2021 May 25; 12. PMID: 34025438    Free PMC article.
Immunotherapy in non-small cell lung cancer: advancements and challenges.
Fei Zhou, Cai-Cun Zhou.
Chin Med J (Engl), 2021 Feb 18; 134(10). PMID: 33595975    Free PMC article.
MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.
Zhengtian Li, Lingling Jiang, +5 authors, Gang Du.
Medicine (Baltimore), 2021 May 26; 100(21). PMID: 34032736    Free PMC article.
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Elin Aamdal, Else Marit Inderberg, +10 authors, Gustav Gaudernack.
Front Immunol, 2021 May 29; 12. PMID: 34046035    Free PMC article.
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, +7 authors, Chuansheng Zheng.
Front Oncol, 2021 May 29; 11. PMID: 34046338    Free PMC article.
Systematic Review.
Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Meng Zhang, Changsong Qi, +8 authors, Jiafu Ji.
J Mol Med (Berl), 2021 Jun 01; 99(9). PMID: 34057552
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Matthew D Galsky, Abdel Saci, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2020 Jun 14; 26(19). PMID: 32532789    Free PMC article.
Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Yuhui Ma, Quan Li, +8 authors, Yongchun Zhou.
Front Oncol, 2021 Jun 01; 11. PMID: 34055609    Free PMC article.
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Xin Huang, Minjun He, +9 authors, Chunyan Lan.
J Immunother Cancer, 2021 May 21; 9(5). PMID: 34011535    Free PMC article.
Overview of Lung Cancer Immunotherapy.
Miguel F Sanmamed, Iñaki Eguren-Santamaria, Kurt A Schalper.
Cancer J, 2020 Dec 11; 26(6). PMID: 33298718    Free PMC article.
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.
Teresa Magnes, Sandro Wagner, +4 authors, Thomas Melchardt.
Int J Mol Sci, 2021 Jun 03; 22(9). PMID: 34067112    Free PMC article.
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Misako Nagasaka, Mohammed Hafiz Uddin, +4 authors, Asfar S Azmi.
Mol Cancer, 2021 Jun 03; 20(1). PMID: 34074295    Free PMC article.
Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy.
Ziwei Guo, Jun Liang.
Cancer Manag Res, 2021 Jun 04; 13. PMID: 34079370    Free PMC article.
Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer.
James Newman, Isabel Preeshagul, +2 authors, Nagashree Seetharamu.
Lung Cancer Manag, 2021 Jun 05; 10(2). PMID: 34084210    Free PMC article.
Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer.
Bolin Chen, Min Yang, +7 authors, Liyu Liu.
Oncol Lett, 2021 Jun 05; 22(1). PMID: 34084219    Free PMC article.
Challenges in bioinformatics approaches to tumor mutation burden analysis.
Francesca Fenizia, Raffaella Pasquale, +7 authors, Nicola Normanno.
Oncol Lett, 2021 Jun 05; 22(1). PMID: 34084222    Free PMC article.
A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
Jie Wu, Lan Li, +4 authors, Bin Xu.
Oncogene, 2021 Jun 11; 40(26). PMID: 34108619
Chemotherapy Knowledge Base Management in the Era of Precision Oncology.
Samuel M Rubinstein, Tarsheen Sethi, +5 authors, Jeremy L Warner.
JCO Clin Cancer Inform, 2021 Jan 08; 5. PMID: 33411619    Free PMC article.
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Lei Sheng, Jing Gao, +5 authors, Lian Liu.
Ther Adv Med Oncol, 2021 Jun 10; 13. PMID: 34104227    Free PMC article.
Immunotherapy in non-small cell lung cancer: Update and new insights.
Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintanta Cortés, María Sereno Moyano.
J Clin Transl Res, 2021 Jun 10; 7(1). PMID: 34104805    Free PMC article.
Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis.
Yuan Tian, Alan Huang, +4 authors, Yuping Sun.
Front Oncol, 2021 Jun 11; 11. PMID: 34109117    Free PMC article.
Systematic Review.
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Kenneth K W To, Winnie Fong, William C S Cho.
Front Oncol, 2021 Jun 12; 11. PMID: 34113560    Free PMC article.
AR Splicing Variants and Resistance to AR Targeting Agents.
Mayuko Kanayama, Changxue Lu, Jun Luo, Emmanuel S Antonarakis.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071114    Free PMC article.
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Shiho Asaka, Ting-Tai Yen, +2 authors, Stephanie Gaillard.
Mod Pathol, 2018 Nov 08; 32(4). PMID: 30401949    Free PMC article.
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Qin Zhang, Liansha Tang, +2 authors, Weimin Li.
Front Immunol, 2021 Jun 15; 12. PMID: 34122422    Free PMC article.
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Giuseppe Bronte, Alberto Verlicchi, +9 authors, Lucio Crinò.
Front Immunol, 2021 Jun 15; 12. PMID: 34122429    Free PMC article.
USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.
Min Li, Yanqin Xu, +6 authors, Xuanming Yang.
Mol Ther, 2021 Feb 19; 29(6). PMID: 33601053    Free PMC article.
Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Wenyu Cao, Xinyue Ma, +3 authors, Qing Zhang.
Biomark Res, 2021 Jun 18; 9(1). PMID: 34134781    Free PMC article.
Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma.
Teng Li, Xiaocong Pang, +5 authors, Junling Li.
Front Oncol, 2021 Jun 18; 11. PMID: 34136375    Free PMC article.
Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort.
Yu-Jie Huang, Zhi-Fei Cao, +6 authors, Zi-Xiang Zhang.
World J Clin Cases, 2021 Jun 19; 9(17). PMID: 34141777    Free PMC article.
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Liuning Li, Guojie Lu, +5 authors, Lin Yang.
Front Oncol, 2021 Jun 22; 11. PMID: 34150625    Free PMC article.
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease.
Parvez Khan, Jawed Akhtar Siddiqui, +6 authors, Mohd Wasim Nasser.
Semin Cancer Biol, 2020 Nov 22; 83. PMID: 33220460    Free PMC article.
Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.
Y Hibino, M Ito, T Satake, S Kondo.
ESMO Open, 2021 Jun 13; 6(4). PMID: 34118770    Free PMC article.
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery.
A Moreira, A Poulet, +25 authors, M Kamal.
ESMO Open, 2021 Jun 13; 6(4). PMID: 34118772    Free PMC article.
Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.
Qi-Fan Yang, Di Wu, +5 authors, Li Liu.
Sci Rep, 2021 Jun 18; 11(1). PMID: 34135424    Free PMC article.
Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis.
Yasuto Yoneshima, Eiji Iwama, +9 authors, Isamu Okamoto.
Sci Rep, 2021 Jun 19; 11(1). PMID: 34140559    Free PMC article.
Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Jeong Uk Lim, Hye Seon Kang, +5 authors, Sang Haak Lee.
J Thorac Dis, 2021 Jun 25; 13(5). PMID: 34164174    Free PMC article.
Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review.
Elisabeth Smolle, Valentin Taucher, +2 authors, Freyja-Maria Smolle-Juettner.
Transl Lung Cancer Res, 2021 Jun 25; 10(5). PMID: 34164273    Free PMC article.
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg.
Nat Rev Clin Oncol, 2021 Jun 26; 18(10). PMID: 34168333
Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Yi Wan, Xin Wang, +8 authors, Li Zhang.
Cancer Med, 2021 May 06; 10(12). PMID: 33949150    Free PMC article.
Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Laurene S Cheung, Lingling Chen, +14 authors, Nicolas Llosa.
J Immunother Cancer, 2021 Jun 10; 9(6). PMID: 34103354    Free PMC article.
Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis.
Li-Ting Lai, Wei-Guo Gu, +5 authors, Chun-Liang Wang.
Aging (Albany NY), 2021 Jun 05; 13(11). PMID: 34086601    Free PMC article.
Systematic Review.
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
Yoon Jung Jang, Dong-Gon Hyun, +6 authors, Jae Cheol Lee.
BMC Cancer, 2021 Jun 28; 21(1). PMID: 34174841    Free PMC article.
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.
Nina Anžič, Fatime Krasniqi, +2 authors, Jasmin Dionne Haslbauer.
Case Rep Oncol, 2021 Jun 29; 14(2). PMID: 34177520    Free PMC article.
Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.
Ling Zhan, Hong-Fang Feng, +4 authors, Sheng-Rong Sun.
Front Endocrinol (Lausanne), 2021 Jun 29; 12. PMID: 34177799    Free PMC article.
Systematic Review.
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc'H, Karen L Reckamp.
Pharmaceutics, 2021 Jul 03; 13(6). PMID: 34205484    Free PMC article.
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy.
Frank J Borm, Jasper Smit, +4 authors, Adrianus J de Langen.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34205572    Free PMC article.
TMB in NSCLC: A Broken Dream?
Sara Bravaccini, Giuseppe Bronte, Paola Ulivi.
Int J Mol Sci, 2021 Jul 03; 22(12). PMID: 34207126    Free PMC article.
Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.
Alexander Chi, Xia He, +4 authors, Jay M Lee.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34208113    Free PMC article.
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.
Alvida Qvick, Bianca Stenmark, +3 authors, Gisela Helenius.
Mol Med, 2021 Jul 05; 27(1). PMID: 34217228    Free PMC article.
Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Qianhui Xu, Hao Xu, +5 authors, Wen Huang.
Cancer Cell Int, 2021 Jul 05; 21(1). PMID: 34217320    Free PMC article.
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Miles C Andrews, Connie P M Duong, +68 authors, Jennifer A Wargo.
Nat Med, 2021 Jul 10; 27(8). PMID: 34239137
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Johnny Duerinck, Julia Katharina Schwarze, +18 authors, Bart Neyns.
J Immunother Cancer, 2021 Jun 26; 9(6). PMID: 34168003    Free PMC article.
Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Zhi-Qiang Tong, Dong-Yuan Wu, Duo Liu, Mei Dong.
Eur J Clin Pharmacol, 2021 Feb 11; 77(8). PMID: 33564898
Systematic Review.
SSAT State-of-the-Art Conference: Advancements in the Microbiome.
Miquell O Miller, Purna C Kashyap, +9 authors, Gareth J Morris-Stiff.
J Gastrointest Surg, 2020 Sep 30; 25(7). PMID: 32989690
Microenvironmental regulation of tumour immunity and response to immunotherapy.
Mark M Kockx, Mark McCleland, Hartmut Koeppen.
J Pathol, 2021 Apr 14; 254(4). PMID: 33846997    Free PMC article.
Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Kristin L Ayers, Tommy Mullaney, +22 authors, Rong Chen.
Oncologist, 2021 Apr 09; 26(7). PMID: 33829580    Free PMC article.
Comparative genomic signatures in young and old Chinese patients with colorectal cancer.
Fei Wang, Huanqing Cheng, +7 authors, Sheng Dai.
Cancer Med, 2021 May 28; 10(13). PMID: 34041865    Free PMC article.
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.
Yuan Li, Zuhua Chen, +2 authors, Jie He.
Cancer Immunol Immunother, 2021 Feb 04; 70(8). PMID: 33533944
Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Charlotte Domblides, Juliette Rochefort, +5 authors, Marie-Caroline Dieu-Nosjean.
Front Immunol, 2021 Jul 20; 12. PMID: 34276690    Free PMC article.
Biomarkers of therapeutic response with immune checkpoint inhibitors.
Poorva Bindal, Jhanelle E Gray, +2 authors, Sonam Puri.
Ann Transl Med, 2021 Jul 20; 9(12). PMID: 34277840    Free PMC article.
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Kana Ono, Hirotaka Ono, +19 authors, Shunichi Sugawara.
Cancer Med, 2021 Jun 15; 10(14). PMID: 34121358    Free PMC article.
Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE-an enhanced deconvolution method.
Elmer A Fernández, Yamil D Mahmoud, +7 authors, María Romina Girotti.
Brief Bioinform, 2020 Dec 16; 22(4). PMID: 33320931    Free PMC article.
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Pan Shen, Liang Han, +2 authors, Shenghao Tu.
Front Pharmacol, 2021 Jul 23; 12. PMID: 34290608    Free PMC article.
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Kenji Morimoto, Junji Uchino, +16 authors, Koichi Takayama.
Oncoimmunology, 2021 Jul 23; 10(1). PMID: 34290909    Free PMC article.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Aaron C Tan, Stephen J Bagley, +18 authors, Mustafa Khasraw.
J Immunother Cancer, 2021 Jul 04; 9(7). PMID: 34215688    Free PMC article.
Systematic Review.
Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.
Weijie Zhou, Dalang Fang, Yongfei He, Jie Wei.
J Gastrointest Oncol, 2021 Jul 24; 12(3). PMID: 34295561    Free PMC article.
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study.
Myeong Geun Choi, Chang-Min Choi, +5 authors, Jae Cheol Lee.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295661    Free PMC article.
International consensus on severe lung cancer-the first edition.
Chengzhi Zhou, Shiyue Li, +84 authors, Nanshan Zhong.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295668    Free PMC article.
Immunotherapy in oncogene addicted non-small cell lung cancer.
Luke McLean, Jose Luis Leal, Benjamin J Solomon, Thomas John.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295674    Free PMC article.
Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer.
Steven Bozinovski, Amanda Vannitamby, +6 authors, Daniel P Steinfort.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295677    Free PMC article.
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Lizza E L Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295685    Free PMC article.
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Boris Duchemann, Jordi Remon, +8 authors, Nathalie Chaput.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295689    Free PMC article.
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Li-Chung Chiu, Shu-Min Lin, +3 authors, Ping-Chih Hsu.
Vaccines (Basel), 2021 Jul 03; 9(7). PMID: 34201650    Free PMC article.
The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Xiaohua Li, Yuntao Wang, +3 authors, Yifeng Bai.
Front Immunol, 2021 Jul 27; 12. PMID: 34305884    Free PMC article.
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression.
Roy Herbst, Jacek Jassem, +5 authors, Filippo De Marinis.
Front Oncol, 2021 Jul 27; 11. PMID: 34307144    Free PMC article.
An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
Huijuan Zhang, Jing Hu, +5 authors, Ping Sun.
Front Cell Dev Biol, 2021 Jul 27; 9. PMID: 34307344    Free PMC article.
The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.
Yuan Tian, Ran Li, +7 authors, Yuping Sun.
Front Oncol, 2021 Jul 30; 11. PMID: 34322382    Free PMC article.
Systematic Review.
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.
Maureen L Drakes, Patrick J Stiff.
Adv Exp Med Biol, 2021 Aug 03; 1330. PMID: 34339029
Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy.
Quan Cheng, Weiwei Duan, +6 authors, Zhiwei Xia.
Front Cell Dev Biol, 2021 Aug 03; 9. PMID: 34336837    Free PMC article.
The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer.
Harry B Lengel, James G Connolly, +9 authors, David R Jones.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359558    Free PMC article.
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Shuyue Wang, Kun Xie, Tengfei Liu.
Front Immunol, 2021 Aug 10; 12. PMID: 34367148    Free PMC article.
Targeting the DNA damage response in immuno-oncology: developments and opportunities.
Roman M Chabanon, Mathieu Rouanne, +3 authors, Sophie Postel-Vinay.
Nat Rev Cancer, 2021 Aug 12; 21(11). PMID: 34376827
Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff.
Nat Med, 2021 Aug 14; 27(8). PMID: 34385702
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Lynette M Sholl, Fred R Hirsch, +35 authors, John W Longshore.
J Thorac Oncol, 2020 Jun 12; 15(9). PMID: 32522712    Free PMC article.
Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma.
Takayuki Sumiyoshi, Toshinari Yamasaki, +6 authors, Shusuke Akamatsu.
Cancer Sci, 2021 May 20; 112(8). PMID: 34009695    Free PMC article.
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis.
Huihui Jiang, Aiqun Xu, +6 authors, Ran Wang.
Cancer Cell Int, 2021 Aug 16; 21(1). PMID: 34391428    Free PMC article.
Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.
Apaar Sadhwani, Huang-Wei Chang, +16 authors, Peter Cimermancic.
Sci Rep, 2021 Aug 18; 11(1). PMID: 34400666    Free PMC article.
TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Teng Li, Han Wang, +8 authors, Zhijie Wang.
Ther Adv Med Oncol, 2021 Aug 20; 13. PMID: 34408796    Free PMC article.
Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
Ilke Tunali, Yan Tan, +9 authors, Matthew B Schabath.
JNCI Cancer Spectr, 2021 Aug 20; 5(4). PMID: 34409252    Free PMC article.
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Qiang Wen, Zhe Yang, +2 authors, Qiang Li.
Front Oncol, 2021 Aug 24; 11. PMID: 34422625    Free PMC article.
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.
Jialiang Yang, Yan Hui, +8 authors, Tonghui Ma.
Front Oncol, 2021 Aug 24; 11. PMID: 34422670    Free PMC article.
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Marcelo V Negrao, Ferdinandos Skoulidis, +35 authors, John V Heymach.
J Immunother Cancer, 2021 Aug 12; 9(8). PMID: 34376553    Free PMC article.
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups.
Francesco Passiglia, Antonio Galvano, +6 authors, Viviana Bazan.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430351    Free PMC article.
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.
Sijia Ren, Anyi Xu, +8 authors, Jianfei Shen.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430363    Free PMC article.
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Yang Ge, Huiyun Zhang, Nathaniel Weygant, Jiannan Yao.
Front Pharmacol, 2021 Aug 28; 12. PMID: 34447305    Free PMC article.
Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma.
Iny Jhun, Daniel Shepherd, +3 authors, Mari Mino-Kenudson.
J Pathol Inform, 2021 Aug 28; 12. PMID: 34447608    Free PMC article.
Lung Cancer Surgery after Neoadjuvant Immunotherapy.
Dirk Stefani, Till Plönes, +4 authors, Clemens Aigner.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439187    Free PMC article.
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.
Irina Palacín-Aliana, Noemí García-Romero, +3 authors, Ángel Ayuso-Sacido.
Biomedicines, 2021 Aug 28; 9(8). PMID: 34440110    Free PMC article.
Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics.
Pierre Murchan, Cathal Ó'Brien, +5 authors, Stephen P Finn.
Diagnostics (Basel), 2021 Aug 28; 11(8). PMID: 34441338    Free PMC article.
Current and Future Development in Lung Cancer Diagnosis.
Reem Nooreldeen, Horacio Bach.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445366    Free PMC article.
Immunotherapy Treatment for Triple Negative Breast Cancer.
Elizabeth R Berger, Tristen Park, +3 authors, Nita Ahuja.
Pharmaceuticals (Basel), 2021 Aug 29; 14(8). PMID: 34451860    Free PMC article.
Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.
Fan Luo, Jiaxin Cao, +5 authors, Hongyun Zhao.
Cancer Cell Int, 2021 Aug 30; 21(1). PMID: 34454491    Free PMC article.
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.
Brittany B Campbell, Melissa A Galati, +26 authors, Uri Tabori.
Cancer Discov, 2021 Feb 11; 11(6). PMID: 33563663    Free PMC article.
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Scott A Tomlins, Daniel H Hovelson, +41 authors, Daniel R Rhodes.
JCO Precis Oncol, 2021 Sep 04; 5. PMID: 34476329    Free PMC article.
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Qian Xu, Xue Zhang, +7 authors, Lian Liu.
Front Immunol, 2021 Sep 07; 12. PMID: 34484242    Free PMC article.
Systematic Review.
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
Wei Xiong, Yunfeng Zhao, He Du, Xuejun Guo.
Front Oncol, 2021 Sep 08; 11. PMID: 34490104    Free PMC article.
Genomic and evolutionary classification of lung cancer in never smokers.
Tongwu Zhang, Philippe Joubert, +58 authors, Maria Teresa Landi.
Nat Genet, 2021 Sep 09; 53(9). PMID: 34493867    Free PMC article.
Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).
Tao Wang, Matthew M Yeh, +2 authors, Gerald M Feldman.
AAPS J, 2021 Aug 18; 23(5). PMID: 34401948
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Beatriz Honrubia-Peris, Javier Garde-Noguera, +3 authors, María Leonor Fernández-Murga.
Cancers (Basel), 2021 Sep 11; 13(17). PMID: 34503087    Free PMC article.
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
William T Atchley, Carolina Alvarez, +4 authors, M Patricia Rivera.
Chest, 2021 Feb 24; 160(2). PMID: 33621599    Free PMC article.
Advancing to the era of cancer immunotherapy.
Yun Wang, Min Wang, Hao-Xiang Wu, Rui-Hua Xu.
Cancer Commun (Lond), 2021 Jun 25; 41(9). PMID: 34165252    Free PMC article.
Towards the understanding of the genetics of somatic mutations.
Xiwei Sun, Jian Yang.
Br J Cancer, 2021 Apr 09; 125(5). PMID: 33828259    Free PMC article.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate Kelley, Bruno Sangro, +21 authors, Ghassan K Abou-Alfa.
J Clin Oncol, 2021 Jul 23; 39(27). PMID: 34292792    Free PMC article.
TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Hui Qiu, Zhiying Shao, +6 authors, Longzhen Zhang.
Front Immunol, 2021 Sep 21; 12. PMID: 34539652    Free PMC article.
Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
Qian Zhao, Butuo Li, +4 authors, Linlin Wang.
Cancer Med, 2021 Aug 15; 10(18). PMID: 34390218    Free PMC article.
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Luiza N Weis, Sara M Tolaney, Carlos H Barrios, Romualdo Barroso-Sousa.
NPJ Breast Cancer, 2021 Sep 15; 7(1). PMID: 34518552    Free PMC article.
The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
Shengjin Dou, Rongrong Li, +9 authors, Guopei Zhu.
Front Immunol, 2021 Sep 24; 12. PMID: 34552580    Free PMC article.
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
Hirofumi Shibata, Shin Saito, Ravindra Uppaluri.
Front Oncol, 2021 Sep 24; 11. PMID: 34552878    Free PMC article.
New Immunotherapeutic Approaches for Glioblastoma.
Gustavo Ignacio Vázquez Cervantes, Dinora F González Esquivel, +2 authors, Verónica Pérez de la Cruz.
J Immunol Res, 2021 Sep 25; 2021. PMID: 34557553    Free PMC article.
FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy.
A Flaus, V Habouzit, +5 authors, F Cachin.
Sci Rep, 2021 Sep 24; 11(1). PMID: 34552135    Free PMC article.
Cancer immunotherapy: it's time to better predict patients' response.
Charlotte Pilard, Marie Ancion, +3 authors, Michael Herfs.
Br J Cancer, 2021 Jun 12; 125(7). PMID: 34112949    Free PMC article.
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.
Virginia Liberini, Annapaola Mariniello, +7 authors, Désirée Deandreis.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572771    Free PMC article.
PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
Yoon Ah Cho, Hyunwoo Lee, +5 authors, Kyoung-Mee Kim.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572886    Free PMC article.
From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
Lishi Wang, Fengxia Liu, +13 authors, Jiafu Ji.
J Pers Med, 2021 Sep 29; 11(9). PMID: 34575691    Free PMC article.
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Dhaneshree Bestinee Naidoo, Anil Amichund Chuturgoon.
Int J Mol Sci, 2021 Sep 29; 22(18). PMID: 34575943    Free PMC article.
Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma.
Qianhui Xu, Shaohuai Chen, Yuanbo Hu, Wen Huang.
Front Genet, 2021 Oct 01; 12. PMID: 34589117    Free PMC article.
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, +15 authors, Alexander Drilon.
JTO Clin Res Rep, 2021 Oct 01; 2(7). PMID: 34590036    Free PMC article.
Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions.
Lin-Rui Ma, Jia-Xin Li, +5 authors, Pei-Yu Yan.
Oncol Lett, 2021 Oct 02; 22(5). PMID: 34594428    Free PMC article.
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.
Vincent Lemaire, Colby S Shemesh, Anand Rotte.
J Exp Clin Cancer Res, 2021 Oct 03; 40(1). PMID: 34598713    Free PMC article.
Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis.
Zhe Zhao, Xinfeng Wang, +4 authors, Xiaoguang Chen.
Front Oncol, 2021 Oct 05; 11. PMID: 34604047    Free PMC article.
Systematic Review.
DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
Jiawei Dai, Minlin Jiang, +7 authors, Caicun Zhou.
Front Oncol, 2021 Oct 05; 11. PMID: 34604048    Free PMC article.
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Yiting Sun, Jianchun Duan, +10 authors, Jie Wang.
BMC Med, 2021 Oct 08; 19(1). PMID: 34615542    Free PMC article.
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells.
Ting Liu, Jizhou Tan, +9 authors, Jiaping Li.
Gut, 2020 Dec 03; 70(10). PMID: 33262196    Free PMC article.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Elaine Chang, Lorraine Pelosof, +15 authors, Marc R Theoret.
Oncologist, 2021 Jul 02; 26(10). PMID: 34196068    Free PMC article.
Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Jhanelle Gray, Jeffrey C Thompson, +2 authors, Charu Aggarwal.
Oncologist, 2021 Jul 04; 26(10). PMID: 34216176    Free PMC article.
Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
Li-Yue Sun, Wen-Jian Cen, +8 authors, Zi-Ming Du.
Cancer Med, 2021 Sep 02; 10(19). PMID: 34469045 &nb